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ABSTRACT OF THE DISSERTATION
Multi-omics Portraits of Cancer
for Arts & Sciences Graduate Students
by
Kuan-lin Huang
Doctor of Philosophy in Biology and Biomedical Sciences
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Associate Professor Li Ding, Chair

Precision oncology demands accurate portrayal of a disease at all molecular levels.
However, current large-scale studies of omics are often isolated by data types. I have been
developing computational tools to conduct integrative analyses of omics data, identifying unique
molecular etiology in each tumor. Particularly, this dissertation presents the following
contributions to the computational omics of cancer: (1) uncovering the predisposition landscape
in 33 cancers and how germline genome collaborates with somatic alterations in oncogenesis; (2)
pioneering methods to combine genomic and proteomic data to identify treatment opportunities;
and (3) revealing selective phosphorylation of kinase-substrate pairs. These findings advance our
understanding of tumor biology on a systematic scale and inform clinical practice of cancer
diagnosis and treatment design.
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Chapter 1: How to paint a multi-omics
portrait of cancer
How to paint a multi-omics portrait of cancer? How do we use big data of bio-molecules ranging
from DNA, RNA to protein to understand each cancer? And how do we use this knowledge to
advance diagnosis and treatment of cancer?

1.1 Genetic predisposition in cancer
A sizable fraction of cancer is heritable1, yet known common variants explain only a limited
percentage of the genetic burden in cancer2. More than 100 genes, mostly tumor suppressors,
have been found to harbor rare, predisposing alleles3. Most reports on germline variants have
focused on single cancer types, although mounting evidence has suggested shared predisposition
factors across cancer types. Previous pan-cancer studies have highlighted pathogenic germline
variants in tumor suppressor genes, including ATM, BRCA1, BRCA2, BRIP1, and PALB2 in adult
cancers in The Cancer Genome Atlas (TCGA)4 and the Collaborative Oncological Geneenvironment Study (COGS)5, as well as TP53, APC, BRCA2, NF1, PMS2, and RB1 using 1,120
pediatric cancer cases from the Pediatric Cancer Genome Project (PCGP)6. As sequencing
projects expand, large-scale, systematic analyses are needed to increase statistical power and to
compare predisposition factors among gene categories and cancer types.

1

Clinical interpretation of germline variants is a pressing challenge. Conflicting claims resulting
from variability in sequencing technologies, analysis pipelines, and interpretations hinder the
application of such knowledge7. Recent American College of Medical Genetics and Genomics–
Association for Molecular Pathology (ACMG–AMP) guidelines provide a systematic method for
interpretation of sequence variants for genetic disorders8; however, a high fraction of variants are
relegated to the unknown significance (VUS) category, often due to rarity and conflicting results
in existing databases and the primary literature. Systematic analyses of high-throughput data
associated with germline variants, such as matching tumor sequencing and mRNA sequencing
data, can provide evidence of functional consequence and further inform clinical interpretation.
For example, paired normal-tumor sequencing analysis of allele fraction can validate whether
variants of tumor suppressors are undergoing positive selection as part of the classic two-hit
model4,9,10 and mRNA analysis can validate whether a germline truncation results in reduced
expression. Of note, the current ACMG/AMP guidelines do not make use of this type of somatic
analysis evidence for evaluation of germline variants.

1.2 Proteogenomics of cancer xenograft models
Profiling of somatic alteration by next generation DNA sequencing (NGS) has entered clinical
practice with the promise of rapid diagnosis of druggable somatic genomic alterations for
personalized cancer treatment11,12. For example, recent analysis of 4,068 samples from 16 cancer
types suggested that repurposing approved drugs based on genomic alterations could provide
individualized treatment options for around 40% of tumors13. However, clinical evidence for this
proposition is limited and has been slow to develop. Further, the signaling and biological effects
2

of somatic mutations are not routinely determined in human tumor samples even though this is a
consideration for rational drug design, response prediction and target prioritization14,15. Finally,
druggable genomic alterations are not detected in the majority of cases tested by NGS3.
Comprehensive proteomic analyses provide a potentially valuable approach to validate genomic
findings as likely biological drivers and to discover discover opportunities for targeted treatment.

Patient-derived xenografts (PDXs) in immunodeficient mice maintain the histological and
molecular heterogeneity of the progenitor human tumor16 and cytotoxic drug responsiveness is
often a transplantable phenotype17. Our previous studies have shown that breast tumor PDXs
recapitulate major genomic signatures and transcriptome profiles of their original breast
tumors18,19. Moreover, drug responses to endocrine therapy in breast cancer PDXs resembled that
observed in the corresponding patient and endocrine therapy resistance patterns were associated
with aberrations in the ESR1 gene16. While comprehensive proteomic characterization of PDX is
still lacking, recent studies using reverse phase protein array have identified similar protein
profiles between PDX and primary tumors20,21. These studies collectively suggest that the PDX
approach is a potentially valuable preclinical model for identification and testing of therapeutic
targets.

1.3 Proteogenomics of cancer xenograft models
Mutations and alterations in cancer dysregulate kinases and signaling cascades. Large-scale
studies of breast cancer have discovered drivers, with genomic and expression changes, in
3

kinases of the PI3K/Akt signaling and TP53/RB signaling/cell-cycle checkpoint pathways22,23.
However, genomic findings provide only indirect inference of phosphorylation activity.
Furthermore large-scale proteomic studies using Reverse Phase Protein Array (RPPA) are
limited with coverage of approximately 200 proteins with available antibodies24-26. The impact of
candidate driver events on direct signaling are therefore seldom explored in the corresponding
tumors. While functional experiments in in vivo systems or model organisms enabled controlled
assessment of the downstream effects, they need to be complemented by in vivo observations
that account for the molecular complexity of each tumor.

Mass spectrometry (MS) is evolving rapidly and has cataloged tens of thousands of
phosphorylation sites (phosphosites). Recent studies by the Clinical Proteomic Tumor Analysis
Consortium (CPTAC) using liquid chromatography (LC) MS/MS have generated
proteomic/phosphoproteomic data sets that more deeply profiled the cancer proteome23,27,28,
providing an opportunity to evaluate regulation of phospho-signaling in cancer. Other MS-based
studies focusing on the kinome have highlighted kinases that are disrupted in cancer29, and
identified complementary genomic and proteomic alterations in a handful of signaling
pathways30. However, characterization of kinase-substrate interaction at a single-residue level
has been largely limited to in vitro and in silico predictions31. Direct observation of kinasesubstrate associations in tumors are required to understand their regulation.

4

Chapter 2: Pathogenic germline variants in
10,389 adult cancers
2.1 Abstract
We conducted the largest survey of rare germline variants in cancer to date, discovering
pathogenic or likely pathogenic variants in 8.9% of 10,389 cases from 33 cancer types. Twentyone genes showed significant enrichments of these variants, aggregating in heavily predisposed
cancers including sarcoma, pheochromocytoma/paraganglioma, and breast/ovarian cancers. The
710 pathogenic or likely pathogenic variants found in tumor suppressors, including truncations
of BRCA1, BRCA2, NF1, ATM, and CHEK2, commonly showed low gene expression (49%)
and loss of heterozygosity/biallelic events (26%). We also discovered an unexpectedly high
number (93) of such variants in oncogenes, including missenses in MET, RET, EGFR and
CCND2 duplication frequently associated with high gene expression (39%). Functionalities of
variants are further established through co-localization with somatic mutations/post-translational
modification sites, family history of carriers and experimental validation of activating RET
alleles. Our results provide the largest predisposition landscape in cancer and reveal potential
oncogenic mechanisms of germline variants.

5

2.2 Results
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Figure 2.1. Predisposition variant discovery in 10,389 adult cancers of the TCGA
PanCanAtlas cohort. (A) A scalable variant calling and data sharing model using ISB Cancer
Genome Cloud (ISB-CGC). (B) Number of germline variants at each step of discovery from
more than 1.46 billion total germline variants called from WES bam files to 1,461 prioritized,
manual-reviewed related to cancer predisposition. 974 pathogenic or likely pathogenic variants
are used in downstream analyses.

7

Data Generation and Sharing on Cloud
The TCGA PanCanAtlas Germline Working Group analyzed germline predisposing variants in
10,389 samples across 33 cancer types. A focus group conducted variant calling on the Institute
for Systems Biology Cancer Genomics Cloud (ISB-CGC) and the resulting calls were shared
among all investigators for quality control and downstream analyses (Figure 2.1A). Specifically,
we dockerized the GenomeVIP variant calling system (github.com/ding-lab/GenomeVIP)32 and
deployed more than 121,000 virtual machines running for over 600,000 hours on the ISB-CGC
during the course of the project. Variant calls from GATK33, VarScan234, and Pindel35,36 were
merged, filtered, and annotated (Methods), resulting in 286,657,499 total exonic variants,
ranging from an average of 33,037 exonic variants per individual of African ancestry to 26,640
of European ancestry (Figure 2.1B). Our data-sharing paradigm effectively facilitated the
analyses required by such an enormous project, avoiding both redundant computation in variant
calling/processing and storage of intermediate analysis files in various local computational
clusters.

The final set of 10,389 samples passed stringent quality control criteria, showing good coverage,
no outlying numbers of variants called, and high concordance with SNP array data (Methods).
Sample quality control analysis of germline-normal samples revealed an average coverage
between 18X and 174X for 151 of 152 predisposition genes known to harbor rare, pathogenic
variants (Methods). The passed variant calls achieved an average precision above 0.99 when
compared to the genotypes obtained through SNP array data. The germline exomes displayed
high quality, with an average TiTv value of 2.88 ± 0.17 and lambda value37 of 0.034 ± 0.003.
8

The median predicted percent false positive calls across 33 cancer types was less than 5%,
ranging from 1.2% (MESO) to 16.1% (KIRC). These resources are shared with the cancer
researcher community on the cloud for further evaluation across institutions worldwide.

Pathogenic Variant Discovery across 33 Cancer Types

We developed an automatic variant classification pipeline called CharGer (Characterization of
Germline Variants, https://github.com/ding-lab/CharGer) by adopting and extending the ACMG–
AMP guidelines8 specifically for rare variants in cancer. CharGer queries clinical information
from ClinVar38, including variant entry submissions and curated disease-gene associations from
OMIM39, MedGen40, and Orphanet41. We also generated gene-specific databases for known
susceptibility genes, including TP53, BRCA1, BRCA2, RET, and TERT (Methods). Further, we
extended the published list of 114 known predisposition genes3, curating a final total of 152
genes that contribute to cancer susceptibility. Overall, each variant is evaluated using data
available for any of 12 pathogenic evidence levels and 4 benign evidence tags that contribute to a
composite score used for automatic classification. Known pathogenic variants in ClinVar and
curated databases are marked as pathogenic, whereas variants with CharGer score > 8 as likely
pathogenic, and those with CharGer score > 4 as prioritized VUSs (Methods).

9

Figure 2.2. Distribution of pathogenic germline variants across genes and cancer types. (A)
Percentage of TCGA cases carrying pathogenic and likely pathogenic variants in each of the 33
cancer types. (B) Comparison of pathogenic variants characterized in this study vs. the previous
TCGA germline study investigating 12 cancer types (Lu et al., 2015a). (C) Frequency of carriers
of pathogenic variants in genes enriched in cancers. Each box indicates the percentage of carriers
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of each gene in the specified cancer cohort. The black outlines indicate the cancer type is
significantly (FDR < 0.05) enriched for pathogenic variants of that gene. The grey outlines
indicate suggestive (FDR < 0.15) enrichment. (D) Counts of pathogenic and likely pathogenic
variants in the oncogenes and tumor suppressors enriched in cancers.

We applied CharGer to classify variants found in our selected TCGA cohort into pathogenic,
likely pathogenic, and VUS groups. CharGer initially prioritized 31,963 variants in these
samples, 1,461 of which were labeled as rare variants (£ 0.05% AF in 1000 Genomes and
complete ExAC r.3.0.1) relevant to cancer, passing manual review in both normal and tumor
samples (Methods). Combining existing database curation and CharGer results, we classified
these into 491 pathogenic variants, 483 likely pathogenic variants and 487 prioritized VUSs
(Figure 2.1C). This catalog of 974 pathogenic or likely pathogenic germline variants expanded
significantly from our previous study, which had focused solely on variants that truncate tumor
suppressors in 12 TCGA cancer types42 (Figure 2.2B).

Across all cancer types, 4.6% of cases (n=482) harbored pathogenic variants and another 4.3% (n
= 445) carried likely pathogenic variants (Figure 2.2A). The frequencies of pathogenic or likely
pathogenic variants vary greatly across cancer types, with as expected high rates in OV (22.1%)
and BRCA (10.7%). Other cancer types that involve tissue types exposed to environmental
factors, such as SKCM (6.8%) and UVM (5%), had lower percentages of carriers. Notably,
23.5% of PCPG, 16.2% of PAAD, and 13.3% of SARC cases carried such variants, suggesting
significant contributions of rare germline predisposition in these cohorts43.

11

We investigated genes with enriched pathogenic or likely pathogenic variants in each cancer type.
Briefly, we first identified cancer types with potential higher enrichment by comparing to
pathogenic or likely pathogenic variants identified in the ExAC non-TCGA cohort. We then
conducted Total Frequency Testing (TFT)44 for one cancer type against all other cancer types,
subtracting the ones with potential enrichment for each gene (Methods). We identified 27
specific cancer-gene associations (FDR < 0.05) and 20 additional suggestive associations
(Figure 2.2C). Pathogenic or likely pathogenic variants of BRCA1 and BRCA2 are highly
enriched in OV and BRCA (FDR < 5.51E-05), as expected, while BRCA2 also showed
significant enrichment in PAAD (FDR = 0.022). PCPG is associated with a wide array of
predisposition factors, including RET, SDHB, VHL, NF1, SDHD, and MAX. Other genes
enriched in multiple cancer types include BUB1B in GBM and LUSC as well as ATM in STAD,
PRAD, PAAD, and LUAD.

On the variant level, we identified 710 pathogenic or likely pathogenic variants in 66 tumor
suppressor genes (TSGs) (Figure 2.2D). Strikingly, we also discovered 93 pathogenic or likely
pathogenic variants in 20 oncogenes, including RET, MET, MPL, TSHR and EGFR. Twenty-two
RET variants are found across 11 cancer types. Some variants appear to be cancer specific; for
example, all of the 3 pathogenic MET p.H1112R variants are observed in KIRP (papillary renal
carcinoma), validating the previously observed co-segregation of the variant in hereditary
KIRP45. For tumor suppressors, we identified a total of 36 BRIP1 variants across 22 cancer types.
ATM and PALB2 variants are both found in 18 cancer types. In contrast, multiple other tumor
suppressor genes showed enrichment in specific cancer types, such as BRCA1, BRCA2 variants
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in BRCA and OV (Figure 2.2C). For example, all of the 4 tumors containing the pathogenic
BRCA1 p.C61G variants in the ring domain are breast invasive carcinoma.

Two-hit Events

To better understand the biological impacts of the discovered variants, we examined the extent of
loss of heterozygosity (LOH) using a statistical test we developed previously4 (Methods). We
discovered 170 significant LOH of pathogenic or likely pathogenic germline variants in tumors
(Figure 2.3A). 22.3% of variants (n=158) in tumor suppressor genes exhibited significantly
greater variant allele frequencies (FDR < 5%) in the tumor compared to their corresponding
normal sample, indicating partial or full LOH. In contrast, significant LOH is only observed in
6.5% pathogenic or likely pathogenic variants of oncogenes (n = 6), possibly due to their gainof-function nature and less selection requirement for the activated mutated allele to be
homozygous.
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Figure 2.3. Systematic identification of two-hit events in TCGA cancers. (A) Identification of
loss of heterozygosity (LOH) in oncogenes and tumor suppressors through comparison of variant
allele frequencies in tumor and normal samples. Each dot depicts one variant. The diagonal line
denotes neutral selection of the germline variant where the normal and tumor variant allele
frequencies (VAFs) are identical. (B) Counts of germline variants showing LOH events in cancer
14

predisposition genes. Count of variants with significant, suggestive, and no evidence of LOH are
shown in red, green and blue, respectively. (C) Candidate biallelic events of pathogenic or likely
pathogenic variants coupled with somatic mutations on gene products of ATM, BRCA2, and
MSH6. Germline variants are colored in red and somatic mutations are in blue. Coupled
germline and somatic events observed in the same case are linked with grey lines.

As expected, strong LOH is observed in cancer types having high hereditary predisposition. The
four OV samples containing BRCA1 p.Q1777fs, p.D825fs, p.W372* and p.E797* each showed
highly significant LOH (FDR <= 3.43E-20), whereas BRCA2 p.E1857fs, p.E294* and p.Y1762*
also showed strong LOH in the other 3 OV samples (FDR <= 3.27E-11). The BRIP1 p.S624*
variant showed pathogenic evidence from three independent ClinVar submitters and displayed
strong LOH evidence (FDR = 1.31E-16) in an OV sample. Some variants showed evidence of
LOH in multiple cancer cases. MET p.H1112R, which was previously shown to cause malignant
transformation of NIH 3T3 cells45 in two of the three KIRP samples (FDR = 2.24E-05, 6.98E-3,
0.26, respectively). RAD51C p.R193* showed LOH in both BRCA and OV (FDR = 3.04E-12
and 5.79E-05, respectively), but not SKCM (FDR=0.933). The positive selection of these
germline variants in the tumor further validates their clinical relevance.

Another manifestation of the two-hit hypothesis is a pathogenic or likely pathogenic germline
variant coupled with a somatic mutation in the other copy of the predisposition gene. We
identified 45 candidate biallelic events when analyzing the tumor in our cohort (Figure 2.3B).
Six germline variants of ATM, including 2 p.T2332fs and 1 each of p.S2289fs, p.R23*,
p.E1267fs and a start loss variant, were coupled with somatic ATM mutations in PRAD, READ,
15

STAD, ESCA, PRAD, and BLCA, respectively. Five cases carrying BRCA2 germline frameshift
truncations, including 2 tumors with p.Y3308*, and 1 each of p.T1598fs, p.A2314fs and
p.Q1037*, also harbored BRCA2 somatic mutations (Figure 2.3B). A COAD case carried MSH6
p.R248fs germline variant/p.R248* somatic mutation that are mutually exclusive in all
sequencing reads, clearly supporting the two-hit abruption of both alleles.

Multiple tumor suppressor genes also showed expression patterns consistent with the two-hit
hypothesis: an African American KIRP patient with an age onset of 35 carried the pathogenic
FH p.S187* germline variant and a somatic splice site FH mutation and showed low FH
expression (at 2.07% of KIRP). A BLCA sample carried the CHEK2 germline p.W93*
compounded by 4 different CHEK2 somatic mutations subsequently showing low CHEK2
expression (at 1.7% of BLCA). Overall, these results provide supporting evidence of the two-hit
hypothesis through LOH and biallelic events of predisposing alleles across tumor types.

Altered Gene Product Expression in Variant Carriers
In addition to expression associated with two-hit events, we systematically investigated the gene
and protein expression of each gene in all carriers of pathogenic or likely pathogenic germline
variants. Briefly, we calculated the percentile of gene expression for variant carriers relative to
other cases in the same cancer cohort. We then conducted a differential expression analysis to
look for genes expressed at different levels in variant carriers (Methods). We identified 11
significant (FDR < 0.05, Wilcoxon Rank Sum Test) and 12 suggestive (FDR < 0.15) gene-cancer
associations (Figure 2.4A-B).
16

In breast cancer, ATM (FDR = 5.3E-4, Wilcoxon Rank Sum Test), CHEK2 (FDR = 3.1E-3),
BRCA2 (FDR = 7.6E-3), and BRCA1 (FDR = 0.032) carriers all showed significant lowerexpression of the respective gene (Figure 2.4B). In PCPG, RET carriers showed higher RET
expression (FDR = 5.3E-4), whereas NF1 (FDR = 0.013), SDHB (FDR = 0.024), VHL (FDR =
0.068), and SDHD (FDR = 0.07) carriers have lower expression. In addition to BRCA, ATM
carriers exhibited significantly lower expression in LUAD (FDR = 0.024) and suggestively in
PAAD (FDR =0.11) and LGG (FDR = 0.12). We then conducted the same analysis using RPPA
data investigating whether the effects extend to the protein/phosphoprotein levels (Figure 2.4CD). Notably, ATM carriers were significantly associated with lower protein expression in 5
cancer types, namely, STAD (FDR = 1.2E-3) and PRAD (FDR = 0.031) in addition to validating
mRNA expression signals in BRCA (FDR = 3.7E-4), LGG (FDR = 0.031), and PAAD (FDR =
0.048). CHEK2 carriers also showed lower protein expression of the Chk2 marker in BRCA
(FDR = 2.5E-3) and LUAD (FDR = 0.028) and suggestively in TGCT (FDR = 0.15).
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Figure 2.4. Germline variants associated with expression impacts. (A) Volcano plot showing
cancer types where the carrier of each gene’s germline variant is associated with significantly
higher or lower expression of the gene transcript. (B) Distribution of gene expression of
pathogenic variant carriers. Each dot corresponds to the gene expression percentile in a case
carrying germline variants relative to other cases of their corresponding cancer cohort. (C)
Volcano plot showing cancer types where the carrier of each gene’s germline variant is
associated with significantly higher or lower expression of the RPPA protein/phosphoprotein
marker. (D) Distribution of protein/phosphoprotein expression of pathogenic variant carriers.
Each dot corresponds to the expression percentile of the RPPA marker in a case carrying
germline variants relative to other cases of their corresponding cancer cohort. The genes shown
18

in (B) and (D) are based on their significant enrichment of pathogenic variants.

Overall, the associated gene expression showed distinct distributions for oncogenes vs. tumor
suppressors (Figure 2.4B). Pathogenic or likely pathogenic germline variants in tumor
suppressors are associated with lower distributions in gene expression than those in oncogenes
(Two-sample Kolmogorov-Smirnov test, p = 8.27E-7): 48.5% of such variants in tumor
suppressors were associated with the bottom quartile of gene expression compared to 22.9% of
variants oncogenes. Further, only 13.0% of the variants in tumor suppressors were associated
with the top 25% of gene expression compared to 38.7% of those in oncogenes, suggesting
divergent transcriptional regulation of tumor suppressor genes and oncogenes carrying
pathogenic or likely pathogenic variants.

On the variant level, tumors with all three MET p.H1112R variants were associated with the all
showed top 25% MET gene expression in KIRP. Notably, 12 cases (including 9 PCPG samples)
carrying predisposing RET alleles, including p.C618R, p.D631Y, p.C634R/W/Y, p.V804M,
p.I852M, p.R912P, p.M918T, showed high RET expression in their respective cancer cohorts.
The high expression of the variant-associated oncogenes in tumor suggests that cancer cells may
preferentially up-regulate pathogenic alleles in these two oncogenes.

Rare Germline Copy Number Alterations

19

We systematically scanned for rare, germline CNVs in the same 10,389 samples, using both
SNP-array data and XHMM analysis as previously described (Fromer and Purcell, 2014;
Ruderfer et al., 2016) on whole exome sequence data (Methods). We identified 4,050 highquality CNVs detected using both technologies, affecting ~27% of the cases (Figure 2.5A). 20%
of the cases have at least one gene impacted by these rare deletions, 10% by duplications. On
average, each case had 0.36 deleted genes and 0.83 amplified genes. 44% of the CNVs affected
only one single gene while 56% impacted multiple genes (Figure 2.5B).
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Figure 2.5. Rare germline copy number variations (CNVs). (A) High-confidence Copy
Number Variations (CNVs) identified through overlapping events in independent analysis of
exome sequencing data (using XHMM) and SNP array data. (B) Characteristics of CNVs
identified in the cohort, including fractions of samples carrying deletions/duplications and the
number of genes affected by each type of CNVs. (C) Deletions of tumor suppressor genes
21

associated with reduced expression. (D) Duplication of oncogenes associated with elevated
expression. For (C) and (D), each dot represents a CNV event found in a specific cancer type
colored according to expression percentile in the cohort. (E) NF1 and RAD51C copy-number
deletion associated with reduced expression each in a breast cancer patient case and BARD1
deletion in a HNSC case. The “control” is chosen as another breast cancer or HNSC case
characterized in the same whole-exome sequencing dataset without any copy number alterations
near this genomic locus.

We then focused on those CNVs that impact our set of 152 cancer predisposition genes and
examined their effect on gene expression (Figure 2.5C-D). Fifteen deletions of tumor
suppressors correspond to the bottom expression quartile in their carriers, while four oncogene
duplications were associated with the top expression quartile. Specifically, we found germline
deletions of tumor suppressors including NF1 deleted in two BRCA cases (expression percentiles
both at 1.2% and 33%, Figure 2.5E) and RAD51C deleted in another BRCA case (expression
percentile = 1.1%). For oncogenes, an CCND2 duplication was found in PCGP. A surprising
PIK3CA duplication was also identified in the blood sample of a PRAD case but not its tumor
sample. We subsequently found clinical data indicated a synchronous Non-Hodgkins lymphoma
for this case, which is a likely source of PIK3CA duplication46. Further, a JAK2 amplification
was only found in the blood but not normal sample of an OV case representing a possible clonal
hematopoietic event. Such examples stress the importance of utilizing both normal and tumor
genomics data in discerning germline, somatic and clonal hematopoiesis events.
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Independent Genomic Evidence Supporting Pathogenicity

We then sought independent evidence to corroborate the pathogenicity of the identified variants,
including (1) significant enrichment in cancer vs. non-cancer cases at a single variant level, (2)
co-localization of variants with pathogenic germline alleles found in pediatric cancers or with
recurrent somatic mutations and (3) co-localization with post-translational modification (PTM)
sites.

To determine whether the pathogenic or likely pathogenic variants are enriched in cancer cases,
we conducted association testing by comparing allele frequencies in TCGA cases vs. non-TCGA
cases based on the Exome Aggregation Consortium (ExAC r.0.3.1) data of 60,706 individuals
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(Methods). We found 175 variants involving 25 genes showing suggestive associations (One-

tailed Fisher’s Exact test, P < 0.05, Figure 2.6A), 7 of which passed the multiple testing
correction threshold (FDR < 0.05) when considering only our previously identified cancerenriched genes. The top associated variants in tumor suppressor genes include ATM p.E1978* (P
= 3.50E-06), BRCA1 p.Q1777fs (P = 2.97E-05), POT1 p.R363* (P = 3.11E-05) and PALB2
p.R170fs (P = 5.20E-04). The results also provided supporting evidence of pathogenicity for
oncogenic variants such as MET p.H1112R (P = 2.00E-03) and MPL p.F126fs (P = 0.0161).
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Figure 2.6. Independent evidence supporting functionality of pathogenic variants. (A)
Pathogenic germline variants showing significant enrichment in TCGA cases compared to nonTCGA cases in ExAC. (B) Variants with co-localizing recurrent somatic mutations (N ≥ 3 in the
TCGA PanCanAtlas MC3 dataset) or pathogenic germline variants in 1,120 pediatric cancers.
(C) Site-specific interaction network of predisposition proteins shows how germline substitutions
occur in experimentally determined binding sites of upstream kinases and other enzymes.
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In our TCGA cohort, we observed 28 pathogenic or likely pathogenic variants previously
discovered in 1,120 pediatric cancers6 (Figure 2.6B), including stop-gained variants in BRIP1,
ERCC3, FANCC, MSH2 and WRN. Further, we observed 23 incidences of germline variants colocalizing with recurrent (n ³ 3) somatic mutations found in the TCGA MC3 cohort (Figure
2.6B). Considering unique variants, these include 8 missense variants in TP53, 4 NF1 truncations
and 2 RET missenses. For example, the TP53 p.R248W is a highly recurrent somatic mutation
(n=94) while being observed as a germline variant in both pediatric rhabdomyosarcoma6 and
LGG. The MEN2-associated allele RET p.M918T seen in PCPG and associated with MEN2B
disorder was also found as a recurrent somatic mutation (n=4), suggesting shared oncogenic
processes in predisposition across pediatric/adult cancers and germline/somatic genomes.

To further evaluate whether this set of 1,461 pathogenic or likely pathogenic variants or
prioritized VUSs discovered in TCGA (Figure 2.1C) can impact a broader patient population,
we examined them in an independent (primarily metastatic) tumor cohort collected at The
University of Texas MD Anderson Cancer CenterCancer Center (MDACC), which consists of
3,026 patients in 19 tumor types. Targeted exome sequencing of 200-300 cancer-related genes
were previously sequenced from these patients based on an institutional clearinghouse protocol
for cancer patients48. Thirty unique variants carried by 63 patients were observed in the MDACC
cohort from 8 cancer types including breastcolorectal, colorectal, head and neck, and
glioblastoma multiforme.
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Finally, to investigate additional functional impact of TCGA germline variants on protein
signaling, we mapped the pathogenic or likely pathogenic variants to known post-translational
modification (PTM) sites in our recently published ActiveDriverDB database49. We found that
55 of 132 (42%) protein amino acid substitutions affected PTM sites in 14 genes, significantly
more than expected from chance alone (median 8 PTM substitutions expected from 1000
Genomes data; permutation test P<10-5).

To illustrate mechanisms of germline variants on signaling networks, we systematically mapped
the PTM-associated substitutions to known site-specific enzyme-substrate interactions49,50
(Figure 2.6C). A surprisingly large fraction (17 of 22) of unique substitutions in 8 of 14 genes
can be mapped to site-specific interactions with upstream kinases and other classes of enzymes.
For example, five substitutions in TP53 potentially affect binding sites of kinases, such as
AURKA, AURKB, and other signaling enzymes, such as MDM2 and EP300. Five VHL variants
occur in binding sites of the NEK1 kinase that promotes its degradation 51. RET p.V804M and
p.R921P potentially affect its auto-phosphorylation sites required for kinase activity 52,53.
Similarly, CHEK2 p.S428F may affect its auto-phosphorylation 54, suggesting that selected
germline variants disrupt and rewire protein signaling networks.

26

Germline Variants Clustering at Kinase Domains

Figure 2.7. Germline variants in the kinase domain of the receptor tyrosine kinase RET.
(A) Pathogenic or likely pathogenic germline variants along the RET protein observed in the
TCGA cohort. (B) Co-clustering of somatic mutations and germline variants in the kinase
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domain of RET and MET shown on 3D protein structures (PDB structures: 21VT, 1R0P, and
1XPD from left to right). Germline variants are colored in red; somatic mutations are colored in
blue; amino acid residues affected by both type of mutations are colored in salmon. (C)
Experimental assessment of the signaling functionality of RET germline alleles. Ligandindependent RET activity was measured through pMAPK/RET/GAPDH normalized to the ratio
observed in wild-type. (D) Experimental assessment of RET germline alleles measured through
pMAPK/ GAPDH normalized to the ratio observed in wild-type.

Interestingly, we observed hybrid clusters in the kinase domain of RET: one includes the colocalized germline variants p.R912P/p.M918T and 10 other somatic mutations (Figure 2.7A-B)
while the other adjacent cluster includes p.I852M along with 5 somatic mutations. Additionally,
we also observed germline VUSs co-clustering with somatic mutations in the kinase domain of
RET and MET (Figure 2.7B) potentially providing additional evidence for pathogenicity. One
MET kinase domain cluster centered around residue p.H1112, where the known pathogenic
germline variant p.H1112R and the somatic mutation p.H1112Y resides. This cluster contained
additional somatic mutations including p.T1114S and the pathogenic p.V1110I and a germline
VUS p.H1097R. We further identified a RET kinase domain cluster containing co-localized
germline VUSs p.R844L/Q, p.R846V and co-clustered VUSs p.R817C, p.E843K (Figure 2.7B),
some of which show additional evidence of functionality. For example, RET p.E843K is
associated with high expression (97th percentile) and potential enrichment in the cancer
population (p=1.7E-4).
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Because of the preponderance of variants in RET especially in and around the kinase domain, we
assessed their functionality by conducting experimental validation of 12 unique germline
variants in RET, including 3 pathogenic variants and 9 VUSs (Methods). Additionally, we
selected a constitutively-active positive control p.C618F (Wells 1994) and a kinase-dead
negative control p.K758M.

We assessed the activity of the RET variants by monitoring the downstream pMAPK levels by
Western blot in the absence of its ligand GDNF (Methods). We first measured RET activity
through the ratio of pMAPK/RET/GAPDH (Figure 2.7C). As expected, the constitutively-active
p.C618F showed ligand-independent activation whereas the kinase-dead p.K758M showed
background level of pMAPK. The MEN2 syndrome-associated p.M918T also exhibited higher
activity whereas all other germline VUSs found in this study did not show significant change in
activity when pMAPK was used as readout.

Activating mutations tend to couple with up-regulation of the oncogenes as seen for RET MEN2
alleles and MET p.H1112R in our cohort (Figure 2.4B) and somatic mutations of receptor
tyrosine kinases55. We thus analyzed the results by measuring RET activity by pMAPK/GAPDH
not controlled for the dynamic RET expression (Figure 2.7D). While p.R912P was previously
shown to co-segregate in familial medullary thyroid carcinoma56, our results demonstrate that it
may also show ligand-independent activation (T-test using pooled SD, unadjusted P = 0.0019).
Multiple other variants also showed minor up-regulation of activity and that could be adaptive in
a permissive environment and thus warrant further investigations (Figure 2.7D).
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Association with Ancestry, Onset Age, and Family History
Previous studies have indicated that predisposing variants can show higher frequencies in certain
ethnicity groups, seen for example in various rates of prevalence of pathogenic BRCA1
alterations across Caucasian, Hispanic, African American, and Asian American cohorts57,58. We
compared rates of pathogenic or likely pathogenic germline variants across ancestries in cancer
cohorts when there were at least 25 cases of each ethnicity using the Total Frequency Test
(Methods, Figure 2.8A). While the power of such analysis is limited at current cohort sizes and
no association reached significance after multiple-testing correction, we found suggestive ethnicenriched predisposing factors: for African cases, BRCA2 is potentially enriched in LUSC (P =
0.01) whereas ATM is potentially enriched in PRAD. In STAD, BRIP1 and RECQL variants are
both exclusively found in 2 Asian cases (P=0.054, Figure 2.8A).

We then examined whether carriers of pathogenic or likely pathogenic germline variants are
associated with a younger age of onset (Figure 2.8B). Specifically, we applied a linear
regression model to find effects of predisposition genes with more than 3 carriers in each cancer
cohort using cancer type as a covariate (Methods). As expected, BRCA1 variants are associated
with younger age of onset in OV (FDR = 7.74E-6) and BRCA (FDR = 0.041) while BRCA2
variants are suggestively associated in both cancers (FDR < 0.08). We also observed ATM
variants associating with younger onset age in STAD (FDR = 1.4E-4), FH in KIRP (FDR =
0.041) and VHL in PCPG (FDR = 0.041).
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To identify the predisposition factors in samples with family history, we compared the presence
of variants in samples with family history of cancer to those lacking family history of cancer.
TGCT and STAD displayed suggestive enrichment of pathogenic or likely pathogenic variants in
family history-positive cases (p=0.04 and 0.07, respectively). Interestingly, when including
prioritized VUSs, we identified more significant enrichments (p=0.019 and p=0.006,
respectively), suggesting predisposition factors in these affected families may exist beyond the
strict pathogenic or likely pathogenic variant set.

Out of 522 samples with a positive family history of cancer reported, 50 individuals were found
to carry pathogenic or likely pathogenic variants (Figure 2.8C). PAAD and TGCT both had 11
samples carrying variants affecting ATM (PAAD-specific), BRCA2 and CHEK2 among other
genes. STAD had 7 samples with rare variants in genes including CDH1, a known causal gene
for hereditary diffuse gastric cancer, as well as others that are not classically associated with
stomach cancer such as POLE. Cancers such as COAD, for which hereditary genetics are well
described, harbor germline variants in expected genes, such as MSH6 and MLH1.
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Figure 2.8. Association of ethnicity, onset age, and family history in pathogenic variant
carriers. (A) Count of pathogenic variants in cancer cases of each ethnicity. The top bar chart
shows the percentage of cases carrying likely pathogenic or pathogenic variants in African
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American, Asians, and Caucasians, whereas the bottom bubble plot shows the frequency of
specific predisposing factor identified in each cohort with greater than 25 cases. (B) Pathogenic
germline variants associated with age at onset in each cancer cohort. The grey violin plot
indicates age at onset distributions of non-carriers whereas each of the colored dot represents one
carrier of the associated gene in that cancer. (C) Predisposition genes in cases with family history
of cancer.

2.3 Discussion

We present the largest catalog of germline variants of cancer to date in 10,389 individuals
spanning 33 cancers (Figure 2.1). A total of 974 pathogenic or likely pathogenic variants
discovered in 8.9% of adult cancer cases, a fraction comparable to recent investigations in
smaller cohorts of pediatric and adult cancers6,59,60. This comprehensive survey allowed us to
establish enrichment of pathogenic or likely pathogenic factors in each cancer (Figure 2.2) from
BRCA1/2 in OV and BRCA to RET/SDHB/VHL/NF1/SDHD in PCPG. Further, the concurrent
systematic discovery of CNVs revealed extremely rare events, such as deletion of NF1 and
RAD51C associated with clear expression changes (Figure 2.5), suggesting the importance of
other germline genomic events beyond SNPs and small insertions/deletions.

Most of the known predisposing factors in cancer are found in tumor suppressors, however an
intriguing smaller set of conditions are associated with heritable activating mutations in
oncogenes, such as MET p.H1112R in hereditary papillary renal carcinoma45. In this study, by
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conducting the first systematic discovery of germline variants in oncogenes, we identified a
striking 93 pathogenic or likely pathogenic variants. Approximately 40% of these variants are
associated with high expression supporting their functionality (Figure 2.4). Our discovery
highlighted oncogenes, including and TSHR, as well as genes previously implicated in cancerrelated syndromes, but whose contribution to adult cancer remained unclear, such as ALK
(hereditary neuroblastoma), RET (Multiple Endocrine Neoplasia 2A/2B) and MPL (Congenital
Amegakaryocytic Thrombocytopenia).

Historically, rare pathogenic germline variants have often been overlooked by classification
systems due to the lack of evidence in currently available databases and the lack of somatic
mutation information in the ACMG/AMP classification system. In this study, we integrated
evidence from other omics data to inform variant interpretation practices. In particular, our
approach demonstrated the utility of tumor/normal matched sequencing for germline variant
interpretation in that they are required to discover two-hit events, including LOH or biallelic
events (Figure 2.3). Further, by analyzing tumor expression data from RNA-Seq, we identified
that approximately half of pathogenic variants were associated with low gene expression in
tumor suppressors (Figure 2.4B), confirming and expanding findings of germline variants in
BRCA1/2 and MSH genes associated with low gene expression61,62. The previously-proposed 50
bp rule63 validated in the gTEX dataset64 stated that truncations in the last 50bp of the coding
sequence are associated with less reduction of gene expression. While our result also confirmed
the rule, it does not dictate the lack of expression effect. Thus, careful analysis of gene
expression data is required to prove any transcriptional effect imparted by truncations.
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We characterized sample and cohort-level interactions between germline variants and somatic
mutations in cancer. Within each individual cancer case, we observed that 18% and 4.5% of
pathogenic germline variants exhibit significant LOH and biallelic events, respectively (Figure
2.3C). At the cohort level, we identified germline variants and somatic mutations affecting the
same residues. While these approaches provide systematic evaluation germline variants, careful
assessments are required to separate effects from compounding factors, such as passenger
somatic copy number events that may induce LOH and non-coding variants affecting
transcriptional regulation.

Germline variants overlapping PTMs suggest signaling as a possible predisposition mechanism
in addition to PTMs found in other inherited disease mutations65 and somatic mutations in cancer
genomes from TCGA66. Beyond the 4 pathogenic variants that directly overlapping PTM sites
and additional proximal variants (Figure 2.6C), multiple prioritized VUSs also showed potential
of modulating PTM. For example, multiple TP53 variants directly replace arginine residues
affected by protein methylation (R110L, R333G, 4x R337H), potentially affecting the target
gene specificity of TP5367. The BRCA1 p.Q1281P variant occurs in a known binding site of the
ATR kinase that phosphorylates BRCA1 p.S1280 in response to DNA damage68. Motif analysis
suggests that the substitution replaces a known kinase binding motif of ATR and induces a new
motif preferred by cyclin dependent kinases (CDKs) thus potentially resulting in the rewiring of
signaling.

Our results also demonstrate the importance of experimental validation of the pathogenic
variants. The pathogenic RET allele p.R912P showed suggestive ligand-independent activation
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(Figure 2.7). However, our assay failed to establish functional change in other alleles of familial
medullary thyroid cancer including p.I852M (currently with conflicting evidence in ClinVar) and
p.R844Q (currently a VUS in ClinVar). It is possible that MEN2-associated alleles exhibit higher
expressivity and have easier to detect molecular functional changes with more sensitive assays
required to assess weaker gain-of-function alleles of oncogenes that tend to show lower
penetrance and their effects may be dependent on cellular context as well. Indeed, additional
epigenetics mechanisms such as up-regulation of gene expression may be required for these
alleles to achieve their activating potential, such as the candidate germline RET VUS p.E843K,
which is associated with enrichment in cancer population, high gene expression and conservation
among homologs that showed no gain of activity in our assay. Additional modifier genes may
also remain to be discovered.

We only identified pathogenic or likely pathogenic alleles in 50 out of 552 cases with family
history of cancer and additional predisposing variants may remain to be discovered. For
example, none of the samples with family history of testicular cancer displayed a pathogenic
variant hit. Further, the STAD and TGCT cohorts showed further enrichment of variant carriers
with family history when extending pathogenic variants to include CharGer prioritized VUSs,
presenting opportunities for discovery of predisposing alleles beyond the currentlyacknowledged pathogenic variants.

Overall, we systematically examined the relationships between functional evidence and clinical
classification. The results showed that each germline allele should be carefully evaluated within
the relevant context of the somatic genome and downstream expression. The same pathogenic or
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likely pathogenic allele often corresponds to similar, yet not identical functional events and
phenotypes across individuals. Further, while our results identified potential associations of rare
variants with age and ethnicity (Figure 2.8), sample sizes of current sequencing cohort limited
the power to observe clinical association at a variant level. Integrating omics datasets of even
larger cohorts, including those focused on specific cancer types, are thus required to expand the
depth of analysis and inform mechanisms of predisposition.
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2.4 Methods

Data Generation
Germline variant calling and filtering
TCGA sequence information was obtained from the database of Genotypes and Phenotypes
(dbGaP). Sequence data from germline and tumor samples were downloaded by the Institute for
Systems Biology Cancer Genomics Cloud (ISB-CGC) from the GDC legacy (GRCh37/hg19)
archive. We selected one germline sample and up to one tumor sample per case according to the
following procedure. Files designated as TCGA MC3 BAMs were prioritized due to their
harmonization. A dockerized version of GenomeVIP was used to coordinate germline variant
calling in the guise of integrating multiple tools: Germline SNVs were identified using Varscan
(Koboldt et al., 2012) (version 2.3.8 with default parameters, except where –min-var-freq 0.10, -p-value 0.10, --min-coverage 3, --strand-filter 1) operating on a mpileup stream produced by
SAMtools (version 1.2 with default parameters, except where -q 1 -Q 13) and GATK (McKenna
et al., 2010) (version 3.5, using its haplotype caller in single-sample mode with duplicate and
unmapped reads removed and retaining calls with a minimum quality threshold of 10). Germline
indels were identified using Varscan (version and parameters as above) and GATK (version and
parameters as above) in single-sample mode. We also applied Pindel (version 0.2.5b8 with
default parameters, except where -x 4, -I, -B 0, and -M 3 and excluded centromere regions
(genome.ucsc.edu)) for indel prediction. For all analyses, we used the GRCh37-lite reference and
specified an insertion size of 500 whenever this information was not provided in the BAM
header.
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All resulting variants were limited to coding regions of full-length transcripts obtained from
Ensembl release 70 plus the additional two base pairs flanking each exon that cover splice
donor/acceptor sites. Single nucleotide variants (SNVs) were based on the union of raw GATK
and VarScan calls. We required that indels were called by at least two out of the three callers
(GATK, Varscan, Pindel). In addition, we also included high-confidence, Pindel-unique calls (at
least 30x coverage and 20% VAF).

We then further required the variants to have an Allelic Depth (AD) ³ 5 for the alternative allele.
A total of 49,123 variants passed these filters. We then conducted readcount analyses for these
variants in both normal and tumor samples. We used bam-readcount (version 0.8.0 commit
1b9c52c, with parameters -q 10, -b 15) to quantify the number of reference and alternative alleles.
We required the variants to have at least 5 counts of the alternative allele and an alternative allele
frequency of at least 20%, resulting in 31,963 variants. Of these, we filtered for rare variants with
£0.05% allele frequency in 1000 Genomes and ExAC (release r0.3.1).

We then selected for cancer-relevant pathogenic variants, based on whether they were found in
the curated cancer variant database or in the curated cancer predisposition gene list, and their
associated ClinVar trait. This resulted in 1,678 variants for manual review using the Integrative
Genomics Viewer (IGV) software69. For candidate germline variants having the same genomic
change as somatic mutations, we further filtered for the germline variants that may have
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originated from contaminated adjacent normal samples by eliminating variants called from
adjacent normal, the VAF in normal < 30%, and co-localizing with any known somatic mutation.
This results in the final 1,461 pass-QC variants for downstream analysis.
We further annotated the corresponding genes of variants as oncogenes or tumor suppressors.
We compiled a gene list by combining the oncogenes and tumor suppressors from Vogelstein et
al. 70 and the GSEA database (Downloaded 2014-11-25). We removed NOTCH1 and NOTCH2
from the oncogene classification in GSEA given their controversial roles. We then further
curated several genes, including additional tumor suppressors (ATR, BARD1, ERCC1, FANCI,
FANCL, FANCM, POLD1, POLE, POLH, RAD50, RAD51, RAD51C, RAD51D, RAD54L, MAX)
and additional oncogenes (AR, STAT3, TERT, MAP2K2).

Genotype data
We used SNP-array derived genotype data of 522,606 SNPs to infer the ethnicity of each sample.
Birdseed genotype files of 11,459 samples were downloaded by ISB-CGC from the Genome
Data Commons (GDC) legacy (GRCh37/hg19) archive and converted by us to individual VCF
files (github.com/ding-lab/birdseed2vcf) for merging into a single combined VCF file. SNParray genotypes were also used to assess the precision of germline variant calling in the exome
(median precision: 0.99).

Somatic mutation calls
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We used TCGA MC3 MAF v3 (updated 17 June 2016) for comprehensive somatic mutation
calls across TCGA cancer samples. Specifically, we used mc3.v0.2.8.PUBLIC.maf
(www.synapse.org/#!Synapse:syn7214402/files/) (Kyle et al., in review).

Clinical data
We used the clinical data provided by the PanCanAtlas clinical working group
(https://www.synapse.org/#!Synapse:syn3241074/files/). For family history information, we used
the Clinical data used by the MC3 working group. Ancestry calls of each sample was provided
by the PanCanAtlas Ancestry Informative Markers (AIM) working group.

Bioinformatics Analyses
Database curation for variant classification
At the gene level, we extended the 114 predisposition genes compiled by Rahman et al.3 to a
total of 152 genes that contribute to cancer susceptibility based on literature review. At the
variant level, in addition to the ClinVar database, we compiled multiple well-curated, genespecific databases for more comprehensive coverage of known pathogenic variants. These
included the IARC TP53 germline mutation database, NHGRI BRCA1 and BRCA2 BIC database
(http://research.nhgri.nih.gov/bic/), ARUP MEN2 database for mutations in RET
(http://www.arup.utah.edu/database/MEN2/MEN2_display.php), and the ASU database
(http://telomerase.asu.edu/diseases.html) for TERT mutations. We included only the BRCA1 and
BRCA2 variants marked as clinically important in the BIC database. We also limited our TP53
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variants to those that were carried by an affected proband and confirmed as a germline variant in
the IARC database. We used TransVar71 and customized scripts to convert all variant entries to
standard HGVSg format to ensure proper matching.

Variant classification pipeline and panel review
Briefly, we developed an automatic pipeline termed CharGer (https://github.com/dinglab/CharGer) to annotate and prioritize variants by adopting the AMP-ACMG guideline. For the
automatic pipeline, we defined 12 pathogenic evidence levels and 4 benign evidence levels using
a number of datasets, including ExAC and ClinVar (parsed through MacArthur lab ClinVar:
https://github.com/macarthur-lab/clinvar), and computational tools including SIFT72 and
PolyPhen73. The detailed implementation and score of each evidence level is as follows:

PVS1, PSC1, PM4, PP2, and PPC1: variants in predisposing genes
Variants in the predisposition gene receive one of these evidence level assignments based on
variant type and mode of inheritance. Truncations in susceptibility genes that harbor variants
with a dominant mode of inheritance are assigned PVS1, but recessive variants in these genes are
assigned PSC1. Protein length changes due to inframe insertions or deletions or nonstop variants
in genes that harbor variants with a dominant mode of inheritance receive a PM4, whereas
recessives receive a PPC1. Finally, missense variants in susceptibility genes are tagged as PP2.

PS1 and PM5: pathogenic peptide changes
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Variants that result in identical peptide changes as a previously known pathogenic variant on
ClinVar (only those marked as Pathogenic but not Likely Pathogenic) or the compiled list are
assigned a PS1. Variants that result in a different amino-acid change at the same position are
assigned a PM5.

PM1: hotspot variants
HotSpot3D74 was run on MC3 somatic mutation calls (hypermutators removed). The protein
structure analysis of HotSpot3D identifies mutation clusters, enriched by recurrent and
neighboring pockets of mutations. If a germline variant was found to be a somatic mutation with
recurrence in at least two samples among all cancer types in a HotSpot3D cluster, then the
variant is flagged with a pathogenic characterization of PM1.
PM2 and BA1: minor allele frequency in populations
Variants that are absent or that show extremely low frequency (MAF < 0.0005) in the ExAC
dataset are assigned a PM2, whereas common variants (MAF > 0.05) receive a BA1.
PP3 and BP4: in silico analyses
Several ACMG scores use in silico evidence to determine disease association. We used evidence
from SIFT72 and PolyPhen75, as annotated by VEP76. Each in silico analysis was taken as one
piece of evidence and if both analyses identified as “damaging” or “deleterious” in SIFT (score
<0.05) and “probably damaging” from PolyPhen (score >0.432), the variant was assigned a
pathogenic characterization of PP3. Conversely, if both in silico analyses identify in opposition
to PP3 characterization (>0.05 for SIFT, <0.432 for PolyPhen), then the variant achieves a
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benign characterization of BP4. The score from each fulfilled evidence level is then summed and
classified as described in Figure 2.1C.

Burden testing of pathogenic variants
We adapted the Total Frequency Test (TFT)44 by collapsing pathogenic and likely pathogenic
germline variants to the gene level. We then used total allele counts of pathogenic variants
identified in the ExAC nonTCGA cohort using the same CharGer classification pipeline for
comparison. We deemed one cancer type shows potentially increased burden of a specific gene if
the TFT test against ExAC returned FDR < 0.15.

We then tested burden of pathogenic variants for each cancer type and each gene against all other
cancer cohorts as controls, subtracting out the cohorts showing suggestive enrichment for the
specific gene in the ExAC analyses. Since all our cohorts are called using the same variant
calling pipeline, it avoids the potential danger of comparing against ExAC, which was done in a
different batch of variant calls. The resulting P values were adjusted to FDR using the standard
Benjamini-Hochberg procedure. We subsequently defined significant and suggestive events in
terms of FDR thresholds of 0.05 and 0.15, respectively.

Loss of heterozygosity (LOH) and biallelic events analysis
We applied our previously developed statistical analysis method regarding LOH 4 to individually
test the missense and truncation germline variant sets. We tested variants in genes carrying
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pathogenic or likely pathogenic variants and used variants in other genes to build the null
distribution. The resulting P values were adjusted to FDR again using the standard BenjaminiHochberg procedure. We subsequently defined significant and suggestive events in terms of
FDR thresholds of 0.05 and 0.15, respectively.

For biallelic events analysis, we systematically examined the cases carrying both a pathogenic or
likely pathogenic germline variant and a missense or truncating somatic mutation in the same
gene. The lolliplots are constructed and modified from the PCGP protein paint
(https://pecan.stjude.org/proteinpaint) based on the specified RefSeq transcript.

Gene expression analysis
TCGA level-3 normalized RNA expression data were downloaded from Firehose (2016/1/28
analysis archive). The expression percentile of individual genes in each cancer cohort was
calculated using the empirical cumulative distribution function (ecdf), as implemented in R. We
then used the two-sample Kolmogorov-Smirnov test to compare the expression percentile
distribution between variants of oncogenes and tumor suppressors. We also applied the
Wilcoxon Rank Sum Test to evaluate the protein/phosphoprotein expression percentile
difference between carriers of pathogenic or likely pathogenic variant and non-carriers in cancers
where there are at least 3 carriers. The resulting P values were adjusted to FDR again using the
standard Benjamini-Hochberg procedure.
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To examine the possible location-based effect of truncations, we fitted a linear regression model
using expression percentile as the dependent variable and a Boolean indicator to label whether or
not the truncation is located at the last 50 base pair of the transcript, controlling for variant
classification and truncation variant type.

RPPA analysis
TCGA level-3 normalized RPPA expression data of the tumor samples were downloaded from
Firehose (2016/1/28 analysis archive). The expression percentile of individual genes in each
cancer cohort was calculated using the empirical cumulative distribution function (ecdf), as
implemented in R. We then applied the Wilcoxon Rank Sum Test to evaluate the
protein/phosphoprotein expression percentile difference between carriers of pathogenic or likely
pathogenic variant and non-carriers in cancers where there are at least 3 carriers. The resulting P
values were adjusted to FDR again using the standard Benjamini-Hochberg procedure.

Detection of germline copy number variation events
Whole exome sequencing data on normal samples from 10,389 cases were used for germline
CNV detection. XHMM was run as previously described77. Base-resolution coverage was
calculated by the GATK DepthOfCoverage module (mapping quality > 20) on 209,486 Ensembl
coding exon intervals (build GRCh37) retrieved from USCS Table Browser. Exon targets with
extreme GC content (> 90% or < 10%) or high fraction of repeat-masked bases (> 25%) or
extreme length (< 10bp or > 10kbp) or low mean depth (< 10) were filtered out. The target-by46

sample depth matrix was mean-centered by target dimension. Then principle component analysis
was run to remove the systematic bias, where the top 152 components were removed (whose
variances were higher than 70% of the mean variances of all components). The resulting depth
matrix was normalized to sample-level z-score. During normalization, targets with high variance
(standard deviation>50) were filtered out. CNVs discovery was performed using the Viterbi
hidden Markov model (HMM) with default XHMM parameters. Quality for each called CNV
was calculated by the forward-backward HMM algorithm, as previously described78.

Array-based CNVs were filtered based on the number of probes (>10), length (>10kb),
frequency (<1%), and absolute segment mean value (|log2(copy-number/ 2)| > 0.1). After
filtering, the array-based CNV callset consisted of 209,559 CNVs found across 6464 individuals.

Association testing of single variants
We conducted association testing of pathogenic germline variants using a one-tailed Fisher’s
exact test where the alternative hypothesis assumes the tested variant is enriched in TCGA cases
compared to non-TCGA cases in the ExAC data (release r0.3.1). For allele numbers (AN) and
allele counts (AC), we used the adjusted counts, where only individuals with genotype quality
(GQ) ≥ 20 and depth (DP) ≥ 10 were included. Vcfanno was used to annotate allele frequencies
of the germline variants. TCGA allele counts were inferred through subtracting ExAC nonTCGA allele counts from ExAC total allele counts. We conducted the single variant association
analysis for all alleles.
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Post-Translational-Modification (PTM) site analysis
We mapped the pathogenic or likely pathogenic variants to known post-translational
modification (PTM) sites in our recently published ActiveDriverDB database49, which contains
millions of variants and hundreds of thousands of PTMs. We specifically investigated the four
most characterized PTM types, phosphorylation, ubiquitination, acetylation, and methylation, all
being central to cancer signaling pathways and involved in chromatin regulation and protein
degradation switches.

Clinical association analysis (ethnicity and age at onset)
For ethnicity analysis, we again adapted the Total Frequency Test (TFT) by collapsing
pathogenic and likely pathogenic germline variants to the gene level. We considered two
ethnicities within the cancer type as the cohorts being compared and conducted the analysis
between Caucasians and Asian or African Americans or Americans whenever there were more
than 25 cases in each cohort.

We used a linear regression model to identify associations between age at onset and germline
variant carrier of predisposition genes. We then tested genes with greater than or equal to 3
pathogenic and likely pathogenic variants and 1% carriers in individual cancer cohorts. For both
the ethnicity and age at onset association analyses, the resulting P values were again adjusted
using the Benjamini-Hochberg procedure.
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Family history analysis
Clinical data collected by TCGA projects can provide insight to the family history and/or cancer
predisposition of the subject. This data was harmonized across projects using four major fields
(Methods). A total of 1,999 patients among 8 cancer types (TGCT, STAD, READ, PAAD,
LIHC, LGG, ESCA and COAD) in our cohort have family cancer history information. Across
these projects, 522 samples have a family history of cancer. We then used the Fisher’s Exact Test
to determine whether these cases showed enrichment of pathogenic variant carrier rate compared
to cases with family history information yet negative family history.

Co-localizing and co-clustering of somatic mutations and germline variants
We used somatic mutation calls from the TCGA MC3 MAF, defining germline variants located
at the same protein residue as recurrent (n ³ 3) somatic mutations as co-localizing. We adapted
our previously published tool HotSpot3D74 (v.1.8.0) to conduct co-clustering of TCGA MC3
somatic mutations and pathogenic or likely pathogenic germline variants in genes with available
PDB structures.

RET variant function assays
HEK293T cells were authenticated by DNA finger printing targeting short tandem repeat (STR)
profiles through Genetica Cell Line Testing. They are negative for mycoplasma as determined by
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the absence of extranuclear signals in DAPI staining. Cells were cultured in DMEM (Corning)
supplemented with 5% fetal bovine serum (FBS) (Thermo Fisher). Constructions expressing
RET variants were generated from a plasmid expressing a wild-type RET (pcDNA3RET9)79
using Q5 site-directed mutagenesis (New England BioLabs). All constructs were confirmed by
sequencing (Supplementary INSERT). Cells were transiently transfected with wild-type or
mutant RET constructs using Lipofectamine 2000 (Invitrogen Life Technologies) in six-well
plates. Twenty-four hours after transfection, cells were switched to medium containing 0.5%
FBS for 24 h before the initiation of 20 minutes of treatment with GDNF (100nM) in a subset of
samples. Cells were lysed in buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate,
1 mM β-glycerophosphate, 1 mM sodium orthovanadate, and 1 µg/ml leupeptin (Cell Signaling
Technology). Protease and phosphatase inhibitors (Roche) were added immediately before use.
Samples (15 ug/lane) were boiled in standard commercial SDS-gel loading buffer and run on
SDS 10% polyacrylamide gels. Immunoblotting was performed on Immobilon-P PVDF
membrane (Millipore). The following antibodies were used for immunoblotting: rabbit
monoclonal anti-phosphor-p44/42 MAPK (Erk1/2) (Thr202/204) antibodies (Cell Signaling
#4370S, at 1:1000 dilution), rabbit monoclonal anti-RET (C31B4) antibodies (Cell Signaling
#3223S, at 1:1000 dilution), rabbit monoclonal anti-GAPDH antibodies (Cell Signaling #5174, at
1:1000 dilution), rabbit monoclonal anti-phospho-RET (Tyr905) antibodies (Cell Signaling
#3221 1:1000 dilution), rabbit monoclonal anti-phospho-AKT (Ser473) antibodies (Cell
Signaling #4060 1:1000 dilution), mouse monoclonal anti-RET (C-3) antibodies (Santa Cruz
Biotechnologies #sc-365943 1:100 dilution). Appropriate secondary antibodies with infrared
dyes (LI-COR) were used, such as donkey anti-rabbit antibodies for the 680nm channel (LI-COR
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926-6807) and donkey anti-mouse antibodies for the 800nm channel (LI_COR 926-32212).
Protein bands were visualized using the Odyssey Infrared Imaging System (LI-COR) and further
quantified by ImageJ.

Code Availability
Analysis codes are available at github.com/ding-lab/PanCanAtlasGermline. GenomeVIP Code
for is available at github.com/ding-lab/GenomeVIP. CharGer code is available at
github.com/ding-lab/CharGer. Birdseed conversion code is available at github.com/dinglab/birdseed2vcf.
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Chapter 3: Proteogenomic integration reveals
therapeutic targets in breast cancer
xenografts

3.1 Abstract
Recent advances in mass spectrometry (MS) have enabled extensive analysis of cancer
proteomes. Here, we employed quantitative proteomics to profile protein expression across 24
breast cancer patient-derived xenograft (PDX) models. Integrated proteogenomic analysis shows
positive correlation between expression measurements from transcriptomic and proteomic
analyses; further, gene expression-based intrinsic subtypes are largely re-capitulated using nonstromal protein markers. Proteogenomic analysis also validates a number of predicted genomic
targets in multiple receptor tyrosine kinases. However, several protein/phosphoprotein events
such as overexpression of AKT proteins and ARAF, BRAF, HSP90AB1 phosphosites are not
readily explainable by genomic analysis, suggesting that druggable translational and/or posttranslational regulatory events may be uniquely diagnosed by MS. Drug treatment experiments
targeting HER2 and components of the PI3K pathway supported proteogenomic response
predictions in 7 xenograft models. Our study demonstrates that MS-based proteomics can
identify therapeutic targets and highlights the potential of PDX drug response evaluation to
annotate MS-based pathway activities.
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3.2 Results

Figure 3.1. Modeling human breast cancer with patient-derived xenografts (n=24). (a)
Illustration of generation and proteogenomic characterization of breast cancer xenograft models.
(b) Somatic mutations of significantly mutated genes of human breast tumor were recapitulated
in xenograft models. Mutation data for 23 WHIMs are shown (exome data were not available for
WHIM47). (c) Variant allele fraction analysis showed clonal representation was consistent
between human breast tumor and xenografts. Genomic driver events, including missenses and
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truncations in TP53 and PIK3CA, were retained in the xenograft models. Each color represents
one xenograft sample.

Proteogenomic Coverage of Breast Cancer Xenografts
We selected 24 patient-derived xenograft (PDX) models established from primary or metastatic
breast tumors for comprehensive proteogenomic characterization (Figure 3.1a). The human
patient cohort was composed of 10 basal, 1 claudin-low (CLDN-low), 9 luminal B, and 4 HER2Enriched (HER2-E) breast tumors based on PAM50 expression subtyping. We conducted DNA
and RNA sequencing respectively for 23 PDX models and in one case Sanger DNA sequencing
of hotspot mutations. Isotope Tagging for Relative and Absolute Quantitation (iTRAQ 4-plex)80
was completed for all 24 PDXs for discovery and Label-Free Quantification (LFQ) for 18 PDXs
for validation and confirmation. The comprehensive proteogenomic coverage allowed us to
systematically assess the somatic mutation profile, copy number variation (CNV), mRNA
expression, protein expression, and phosphosite levels and localizations.

We examined somatic mutations in significantly mutated genes of breast cancer in 12 human
tumors and their matching PDXs. Most key somatic mutations in these genes were preserved
(Figure 3.1b), validating the genomic fidelity of these PDX models. However, recurrent breast
cancer mutations were not detected in two PDX models (WHIM 17 and WHIM 46). While
sequencing data were not available for the matched progenitor human tumors, the germline SNPs
of human blood normal samples matched with the PDX tumors, validating their patients of
origin. Follow-up histological and RNA-seq analyses suggested WHIM17 and WHIM46 are
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EBV-positive human lymphoproliferative cells arising in the NOD/SCID/g mouse strain81
(Methods).

We then compared the variant allele fractions (VAFs) of exonic somatic mutations in human
tumors and derived xenografts when both are available. We found comparable or higher VAFs in
xenografts, potentially due to higher tumor purity and selection of some mutant alleles by loss of
heterozygosity in PDX models (Figure 3.1c). The relatively high, positive VAF correlation (R =
0.66) implied similarity between human samples and their respective xenografts, consistent with
our previous report19. Importantly, all PIK3CA and TP53 somatic mutations in the 12 originating
human tumors were detected in respective xenografts with comparable or increased VAFs
(Figure 3.1c). Among the 22 breast cancer PDX models, 14, including 7 of the 8 basal tumors,
harbored TP53 mutations, 5 luminal B PDXs had ESR1 mutations, and 5 luminal B and 1
CLDN-low xenografts carried PIK3CA mutations.
We quantified mRNA expression of 16,209 unique human genes from RNA-Seq data for these
24 models. We also applied two distinct MS data acquisition approaches (Methods), iTRAQ and
LFQ, to quantify the expression ratios of 12,794 human proteins (11,879 genes) and 8,648
proteins (8,035 genes), respectively. A total of 56,874 phosphosites were also confidently
identified using iTRAQ. After filtering for observation in at least 10 out of 24 samples (4 out of
9 of the iTRAQ experiments), the relative abundances of 10,069 proteins and 36,609
phosphorylation sites were quantified across tumors by iTRAQ and used in subsequent analyses
in this study. The technical replicates in the LFQ (WHIM2 and WHIM16) and the iTRAQ
(WHIM13) sets showed high correlation in protein expression levels (R > 0.85). Further,
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phosphosite expressions also showed high correlations in technical replicates (WHIM13) of the
iTRAQ experiment (R=0.82), validating the technical reproducibility of our proteomic and
phosphoproteomic datasets. Of note, while iTRAQ and LFQ quantification were conducted
separately and based on different features of the LC-MS data collected from the Q Exactive mass
spectrometer (i.e. reporter ion intensity and MS1 peak area, respectively), our analysis showed
reasonable correlation between the two measurements after normalization (R = 0.61). The two
datasets utilizing the same PDX models but different workflows enabled cross-method validation
of global proteomic results.

Integration and Comparison across DNA, RNA, and Protein Data
We first evaluated the correlation between mRNA expression and protein abundance
measurements from the iTRAQ experiment (Figure 3.2a) for these 24 PDX models: 83.6% of the
genes with sufficient data showed positive correlations with a median Pearson R = 0.536. We
investigated whether the trend of mRNA-protein correlations were associated with specific
KEGG pathways82, finding that metabolic pathways involved in house-keeping functions are
enriched for genes showing high, positive correlation. For example, genes in the glutathione
metabolism pathway showed the highest enrichment for positive correlations (KolmogorovSmirnov test, FDR = 5.6e-07). Interestingly, we observed that genes in the ribosome (FDR <
2.2e-16), spliceosome (FDR = 2.0e-13), RNA transport (FDR = 1.7e-5), RNA polymerase (FDR
= 1.8e-4), and oxidative phosphorylation (FDR < 2.2e-16) pathways showed relatively lower
correlation between mRNA and protein level. These pathways were enriched for genes that do
not require translated proteins for their biological functions. Similar pathway-specific pattern of
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positive and negative enrichment of correlations were observed by LFQ. The high degree of
mRNA-protein correlation observed in the PDX samples is consistent with recent results
obtained for human breast tumors83 and colorectal cancer84, suggesting that PDXs closely mimic
the respective human breast tumors in their relationship between mRNA and protein.

We then examined the correlation of CNV, mRNA, and protein expression levels for several key
genes for breast cancer biology: EGFR, ERBB2 (HER2), ESR1, GATA3, PGR, PIK3CA,
AKT1/2/3, MTOR, and TP53. In most cases, we observed consistent relationships between CNV,
mRNA, and protein expression levels. Compared to PDXs of non-luminal subtypes, luminal B
breast cancer xenografts, as expected, showed higher mRNA and protein expression of ESR1 and
PGR, consistent with their positive ER and PR status (Figure 3.2b). 5 out of the 6 PIK3CA
mutations were observed in luminal B PDXs, which tended to also show higher mRNA and
protein expression levels of GATA3. In contrast, a larger proportion of basal PDXs expressed
higher protein levels of EGFR. Strong HER2 expression at the mRNA, protein and
phosphoprotein levels were detected in WHIM8 and WHIM35, both derived from HER2positive breast cancers. Overall expression patterns for key genes were consistent with the
clinical subtype diagnosis across CNV, mRNA, protein, and phosphosite analyses.
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Figure 3.2. Correlation analysis across DNA, RNA and protein levels in PDX samples. (a)
Correlation between mRNA and iTRAQ protein expression levels identified pathways with
significantly concordant or discordant mRNA-protein expressions. Genes were aligned along the
x-axis by the rank of their Spearman correlation coefficient between mRNA and protein
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expression levels. Each color represents one significantly associated pathway, and each bar
represents one gene in the pathway. (b) Proteogenomic summary of xenograft shows
relationships among mutation, CNV (normalized log-R ratio), mRNA (log-transformed and
normalized RSEM values), proteomic (normalized log2 ratio to reference), and
phosphoproteomic expression (normalized log2 ratio to reference) levels of breast cancer-related
genes in 24 PDX samples across 4 intrinsic subtypes. Expression values from each dataset were
calculated as described (Methods) and truncated to a maximum of 10 and a minimum of -10 for
visualization.

Proteomic Subtyping of Xenografts and Human Breast Tumors
Molecular subtyping of breast cancer based on mRNA expression profiles has been shown to
correlate with prognosis and has treatment implications85,86. As expected, transcriptome
clustering based on PAM50 genes from RNA-Seq data largely reproduced intrinsic subtypes of
the breast tumors (Figure 3.3a). To explore proteomic and phosphoproteomic subtype
classifications in xenograft models, we conducted unsupervised clustering of proteomes and
phosphoproteomes of the 24 xenograft samples based upon the top 436 variably expressed
proteins showing a standard deviation greater than 2 from the iTRAQ proteome. Two distinct
clusters emerged: one contained all basal tumors and the only CLDN-low tumor (WHIM12),
while the other included all luminal B and HER2-E breast tumors; HER2-E tumors did not show
a proteomic expression profile distinct from luminal B samples (Figure 3.3b). Clustering analysis
using the same gene markers from the transcriptome and the LFQ proteome further supported the
separation into these two proteomic subtypes, although the minor differences between the
transcriptome and the proteome clustering suggested distinctions between mRNA and protein
59

levels. The proteomic subtypes defined by the top 968 most variably expressed mouse host
proteins did not segregate based on luminal and basal subtypes. Besides differing in mRNA
expression, luminal and basal breast cancer PDXs also showed consistently distinct proteomic
expression profiles, supporting their distinct biological origins.

We then utilized the iTRAQ phosphopeptide expression data to infer phosphoproteomic
subtypes. 1,737 unique phosphosites with standard deviation greater than 2.5 were included to
conduct hierarchical clustering (Figure 3.3c). These analyses of the phosphoproteomic data
produced two major clusters segregating the luminal B and basal subtypes. Again, the
WHIM37/WHIM47/WHIM26 group and the WHIM17/WHIM46 group, as observed in the
proteome clustering, grouped closely together. Gene and protein expression of lymphoid lineage
markers showed high expression of CD20 and JAK3 in WHIM17 and WHIM46 (Methods),
consistent with their positive EBV status and histological diagnosis as human
lymphoproliferative cells arising in an immunocompromised mouse background. Overall, while
the basal and luminal clusters remain consistent, the hierarchical distances between PDX
samples within the two major clusters differ between data types. The departure of proteomic and
phosphoproteome subtypes from mRNA expression-defined subtypes suggests independent
layers of molecular heterogeneity provided by distinct proteomic analyses.
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Figure 3.3. Unsupervised hierarchical clustering of breast cancer PDX transcriptomes,
proteomes, phosphoproteomes and combined PDX and human breast tumor proteomes. (a)
Transcriptomic clustering of PDX breast tumors based on the PAM50 gene expression markers.
(b) Proteomic clustering of PDX breast tumors based on the top 436 variably expressed proteins.
(c) Phosphoproteomic clustering of PDX breast tumors based on the top 1,737 variably
expressed phosphosites. (d) Proteomic clustering using only 133 non-differential expressed
proteins between WHIM and human breast tumor samples. The clustering reproduced the basal61

enriched and luminal-enriched clusters, where PDX (n = 24) and TCGA human breast tumor
samples (n = 77) cluster based on their subtypes. The non-differentially expressed proteins were
identified through a t-test with FDR > 0.3 between the PDX and the TCGA human tumor
samples. The PDX tumors are labeled by their WHIM IDs whereas the human tumors are not
labeled.

We then investigated whether human proteomic subtypes could be recapitulated in PDX models
by including an additional 77 proteomes from TCGA human tumors that were processed
concurrently in the iTRAQ experiment83 (Methods). To reduce clustering bias imbued by the
mouse contribution to the proteome in the PDX samples, we excluded proteins showing
differential expression between human tumor and xenograft (t-test, FDR £ 0.3). Additional
requirements, including the presence of detectable protein in more than 10 samples and
minimum difference of 2 standard deviations in the merged proteome, resulted in 133 proteins
qualifying for un-supervised clustering. Consistent with the subtyping analysis of the 24 PDXs
alone, we identified two major clusters: one that included all but one basal breast tumor and the
other comprised mostly of luminal tumors (Figure 3.3d). Similar to the proteomic subtypes of the
PDX cohorts, luminal tumors and HER-2 tumors did not show clear separation, although several
sub-clusters were identified. Importantly, xenograft proteomes clustered adjacently to the human
proteomes of their respective subtypes, validating the fidelity of basal and luminal proteomic
signatures discovered in PDXs.
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To search for defining markers between the basal and luminal B subtypes, we conducted
differential expression analysis between the PDXs of the respective subtypes. We found several
proteomic markers that were differentially expressed in both the LFQ and iTRAQ datasets (t-test,
FDR £ 0.05), including SPR, GSTP1 and SERPINB5. We then conducted gene-set enrichment
analysis based on the Reactome pathway database87 to investigate patterns of differential
expression (Methods). The basal subtype breast tumors were up-regulated in most of the
significantly differentially-expressed pathways (FDR £ 0.01) identified by both LFQ and iTRAQ
datasets, including extracellular matrix organization, cell cycle, and collagen formation. In
comparison, the luminal B breast tumors showed higher expression in genes related to organelle
biogenesis and membrane trafficking.

Activated Pathways Revealed by Phosphorylation Profiles

Cancer driving somatic events trigger major changes in downstream signaling to launch the
tumorigenic cascade88. To search for tumor-specific activated pathways in PDX tumors, we
systematically evaluated and compared phosphoproteome profiles of gene sets from KEGG
signaling pathways (Methods). Phosphorylation enrichment analysis identified 12 significantly
activated pathways, including Ras, MAPK, and NFκB signaling, in 4 xenografts (FDR £ 0.01).
WHIM9 exhibited elevated phosphorylation of the MAPK signaling pathway (FDR = 9.69e-6,
Figure 3.4a). Interestingly, WHIM9 carried a recurrent somatic mutation, KRAS p.A146V89,90,
which may have driven canonical MAPK pathway activation. Further, WHIM12 exhibited
activation of the Ras signaling pathway (FDR=4.28e-5), along with an outlier protein expression
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of MET, a receptor tyrosine kinase upstream of the Ras signaling pathway (Figure 3.4b).
Interestingly, WHIM17 and WHIM46, both harbored BTK and PLCG2 protein overexpression,
exhibited overall high phosphorylation of the NFκB signaling pathway (FDR = 6.94e-3, 4.53e-5
respectively). This observation further supports the strong similarity between these two PDX
models based on protein/phosphoprotein clustering (Figure 3.3b,c) and their classification as
EBV-positive lymphoproliferation.
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Figure 3.4. Activated signaling pathways detected through pathway phosphorylation
enrichment analysis. (a) Activation of the MAPK signaling pathway in WHIM9. (b)
Activation of the Ras signaling pathway in WHIM12. Phosphorylation levels of each protein
in the pathway relative to the cohort of 24 PDX models are shown by the color scale of red
(high) to blue (low). Proteins with no phosphorylation data are colored in green.
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While pathways such as PI3K/AKT/MTOR are known to be activated across the majority of
breast tumors88, our analysis shows that other complementary tumorigenesis-related pathways
including RAS/MAPK are also activated in a small set of breast tumors due to specific genomic
or proteomic alterations, representing alternative treatment opportunities. In addition, our
phospho-proteomic analysis revealed activation of signaling pathways not readily predicted by
genomic data.

Complementary Genomic/Proteomic Druggable Targets
We examined promising drug targets in each tumor by surveying the genome and expressed
proteomes. Specifically, we compiled a list 76 druggable genes, along with their respective
drugs, from established public databases (Methods). Six PDXs, representing 20.8% of the tumors
in this study, harbored druggable somatic mutations, including PIK3CA p.H1047R and KRAS
p.A146V in WHIM9, PIK3CA p.H1047R in WHIM16 and WHIM24, PIK3CA p.E545K in
WHIM18, PIK3CA p.E542K in WHIM20, and SF3B1 p.K700E in WHIM26.
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Figure 3.5. Outlier expression analysis identified druggable events at mRNA expression,
protein expression, and protein phosphorylation levels in 24 breast cancer PDXs.
Druggable outlier events identified at (a) the mRNA and protein and (b) protein and
phosphopeptide expression levels. Each color represents one xenograft sample. Key outlier
events validated in this study are labeled by text. (c) Immunochemistry staining verified
outlier expression of HER2 in WHIM8 and WHIM35, RAF1 in WHIM9, and FGFR2 in
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WHIM16.
While activating mutations in oncogenes can be targeted by treatments, aberrantly overexpressed or activated protein products, such as HER2, also presents exploitable treatment
opportunities91-93. We sought genomic and proteomic evidence of over-expressed genes/proteins
or proteins with highly phosphorylated sites. We defined outliers as expression values exceeding
the 1.5 interquartile ranges (IQR) above the third quartile of the cohort (Variations of Box Plots),
and rank ordered them by the outlier score. We further required CNV outliers to be validated
with outlier expression in either the mRNA or protein level to rule out up-regulation events due
to technical artifacts or passenger events (Methods). mRNA and protein expression outlier scores
showed a moderate positive correlation (Figure 3.5a, R = 0.516), but mRNA outlier expression
did not guarantee high protein expression (e.g., AKT2 and FGFR2, Figure 3.5a). Similarly, we
observed a fraction of phosphosite outliers not detected at the protein level (Figure 3.5b, R =
0.548). Consequently, identifying post-transcriptional and post-translational events to capture
potential druggable treatment opportunities requires consideration of protein expression as well
as gene expression.

Applying this druggable outlier detection strategy across CNV, mRNA, protein, and protein
phosphorylation levels, we identified over-expressed druggable genes in 26.1% and 47.8% of
PDXs at the CNV and mRNA levels, respectively (Figure 3.6). These events recapitulated
known druggable opportunities, such as the PIK3CA copy number amplification in WHIM4 and
ERBB2 (HER2) copy number amplification in WHIM35. Expanding to iTRAQ protein
expression outliers allowed us to uncover druggable targets in 19 out of the 24 PDXs (79.2%),
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while considering phosphosite outliers covered 22 of the 24 PDXs (91.7%). A significantly high
fraction of protein outliers overlapped between the LFQ and iTRAQ datasets (Fisher's Exact
Test, P = 2.013e-05), providing validation of our findings.
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Figure 3.6. Druggable outlier events identified at CNV, RNA, protein, and phosphosite
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levels of 24 PDX models and 77 TCGA human breast tumors. (a) Outlier analysis
The identified
proteomic outliers
included multiple
known druggable
targets involved in
the PI3K, RTK,
MAPK signaling
pathways and

revealed potentially druggable events in the RTK, PI3K, MAPK signaling, genome integrit
pathways at various frequency and magnitudes across 4 breast cancer subtypes. Selected

genes with any outlier score greater than 2.5 or in the key oncogenic pathways, including t
PI3K, RTK, MAPK signaling pathways, are shown. (b) Comparison of protein expression
outliers of selected druggable genes in PDX and human breast tumors. (c) Comparison of

over-expressed phosphosite outliers of selected druggable genes in PDX and human breast

tumors. Key outlier events reaching the outlier definition threshold or validated in this stud
are labeled by text.

other oncogenic processes (Figure 3.6). For instance, HER2 was found to be the top outlier at the
protein expression level in 2 HER2-E xenografts, WHIM8 and WHIM35; the phosphosites of
HER2 were also identified as outliers. Immunohistochemistry experiments validated the high
HER2 protein expression on the cell membranes of WHIM8 and WHIM35 (Figure 3.5c).
Further, AKT1, AKT2 and AKT3 proteins were outlier expression candidates in WHIM35,
WHIM20 and WHIM43, and WHIM4, respectively, providing proteomic validation of
previously observed AKT up-regulation at mRNA expression level in breast cancer88. Other
outlier proteins included IDH1 in WHIM9 and WHIM30, FGFR4 in WHIM11 and WHIM26,
and both BTK and JAK3 in the EBV-positive WHIM17 and WHIM46. Many of these protein
outliers aligned with up-regulation in their corresponding phosphosites, including phosphosites
on AKT1, AKT3, BRAF, FGFR4 and HSP90AB1 (Figure 3.5c). We also discovered additional
outlier phosphosites in other proteins including CTNNB1, ARAF, and HSP90B1. Finally, we
identified outlier FGFR2 in WHIM16 and high RAF1 in WHIM9 and further validated their high
protein expression status of by immunohistochemistry analyses (Figure 3.5c). As diverse sets of
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proteomic outliers are identified across PDXs, effectively inhibiting such activation events will
be required when designing targeted treatment strategies to each individual breast tumor.

Notably, for 80.6% of proteomic outlier events, we were able to identify human tumors from the
77 TCGA samples83 showing the same outlier protein expression through outlier score or ranking
(Methods, Figure 3.6b). For example, we observed outlier HER2 expression in 5 HER2-E and 4
luminal B human breast tumors. Further, a basal human sample carried both the outlier FGFR2
and FGFR4 expression, validating the findings in WHIM16, WHIM26 and WHIM11. Basal
human breast tumors also carried protein expression outliers in IDH1, EGFR and MAP2K1
(Figure 3.6b). Phosphosite outlier expression events showed a moderate rate of validation in the
same human cohort (48.8%, Figure 3.6c), suggesting its transient nature and potential microenvironmental effects on protein phosphorylation. As expected, HER2-E and a few HER2positive luminal B tumors carried outliers in HER2 phosphosites including p.T701, p.T1240 and
p.Y1248. ARAF phosphosite outliers, such as p.S299, were found in both human and PDX
samples, validating our previous finding in the human cohort12. Interestingly, we identified
outlier phosphosites in genes not previously implicated in breast cancer through genomic
profiles, such as BRAF p.S447, p.S750 and HSP90AB1 p.Y56 and p.S169 (Figure 3.6c). Our
results demonstrated that proteomic outlier events, like genomic driver mutations, are
consistently observed in PDXs and human tumors. Some protein outlier events might represent
“proteomic drivers” of tumorigenesis and therefore potential drug targets in breast tumors.
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Targeted Treatments Using Breast Cancer Xenograft Models

Figure 3.7. Targeted treatments of breast cancer xenografts. (a) Western blot of HER2
protein and HER2 p.Y1248 expression levels in 5 WHIM models (WHIM6, WHIM8,
WHIM12, WHIM14, and WHIM35). (b) In vivo treatment responses to lapatinib in 4 PDX

72

models including two HER2 positive lines (WHIM8 and WHIM35) and two basal lines
To validate the
identified
druggable events,
we conducted
treatment
experiments
targeting HER2

(WHIM6 and WHIM14). The response is measured in fold change (%) of tumor volumes
after 2 weeks of vehicle or lapatinib treatment. (c) Immunochemistry staining of AKT

phosphorylation status in WHIM16, WHIM18, and WHIM20 in response to PI3K inhibito
TAK-117, mTOR inhibitor TAK128, and TAK-117/TAK-128 combined. (d) In vivo

treatment responses to PI3K/mTOR inhibitors (TAK-117/TAK-128) of WHIM16, WHIM1
and WHIM20. Values were represented by tumor volume [mm3] every 3 day following
treatment.

and PI3K pathways on selected PDX models. Four PDX models were chosen to address HER2
targeting using lapatinib, an oral HER2 kinase inhibitor. These include 2 HER2-E PDX models
WHIM8 and WHIM35, both with high HER2 protein and phosphoprotein expression, and 2 low
HER2 expressing, basal-like PDX models WHIM6 and WHIM14. Western blotting suggested
high HER2 expression and phosphorylation of HER2 p.Y1248 in both HER2 positive tumors,
WHIM8 and WHIM35 (Figure 3.7a). Unexpectedly, high levels of HER2 p.Y1248
phosphorylation was also detected in WHIM14 by Western blotting. In contrast MS-based
phosphoproteomics also detected high levels of HER2p.Y1248 in WHIM8 and WHIM35, but not
in WHIM14, which was more consistent with the known biology of the models. Antibody-based
diagnosis of HER2 activation in WHIM14 was possibly due to cross-reaction of the Y1248
antibody with the pY1172 site of EGFR that bears high sequence similarity around the pY
residue (..GTPTAENPEy1248LGLDVPV-CO2H vs. ..GSTAENAEy1172LRVAPQ..). As expected,
WHIM8 and WHIM35 were growth inhibited (Wilcoxon Rank Sum Test, P = 2.7e-5, 4.8e-7) by
lapatinib, whereas WHIM6 was not (P = 0.65) (Figure 3.7b). Interestingly, WHIM14 also
showed significant reduction in tumor growth by lapatinib (P = 4.3e-3). Upon further exploration
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with a lower, clinically achievable dose of lapatinib for chronic treatment (30mg/kg compared to
220mg/kg in the previous experiment) over 48 days, significant but weak tumor growth
inhibition was again achieved (P = 0.0311). However, WHIM14 did not respond to HER2/HER3
antibodies trastuzumab or pertuzumab (P = 0.250 and 0.181, respectively). Thus, the response of
WHIM14 to lapatinib was likely due to inhibition of EGFR not HER294,95. While WHIM6 also
showed elevated EGFR protein level, WHIM14 showed notably higher EGFR phosphorylation
based on both mass spectrometry (Figure 3.2b) and western blotting (Figure 3.7a), which could
account for their different response to lapatinib. Two basal and one HER2-E human breast
cancers harbored outlier EGFR expression (Fig 6b), suggesting EGFR remains a potential
therapeutic target in a subset of breast cancers that has yet to be fully realized clinically.

The PI3K/AKT/mTOR signaling pathway is altered in approximately 77% of breast tumors88 and
multiple drugs targeting its components, including Class I PI3Ks, AKTs, and mTORs, are
already in clinical trials96. Among these, a combination of everolimus and exemestane has been
approved for treating advanced ER-positive breast cancers resistant to non-steroidal aromatase
inhibitors97. Promising activity has also been reported for direct inhibitors of PI3K98,99.
However, mutations in PIK3CA and other genetic alterations at the genomic level have so far
failed to closely predict therapeutic responsiveness to PI3K pathway inhibitors98. We therefore
hypothesized that combined genomic and proteomic indication of PI3K signaling activation is
necessary for the prediction of treatment response. Our integrated approach identified 6
xenografts that harbored complementary genomic and proteomic druggable events in the PI3KAKT pathway. In particular, WHIM16 harbored a hotspot PIK3CA p.H1047R mutation, whereas
WHIM18 and WHIM20 each carried a hotspot PIK3CA p.E545K mutation. WHIM20 also
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showed an additional outlier protein expression of AKT2 and WHIM18 also expressed AKT2 at
a near outlier level that may combine to activate PI3K pathway signaling (Figure 3.6). Since the
treatments were applied to later-passage PDX models relative to the ones we conducted
proteogenomic analysis on, we performed immunohistochemistry to validate the phosphorylation
of AKT p.S473. WHIM18 and WHIM20 showed detectable AKT p.S473, which was not
observed in WHIM16 (Figure 3.7c).

We conducted combinatorial treatment experiments by applying an alpha specific PI3K inhibitor
(TAK-117) and/or an mTORC1/2 inhibitor (TAK-228) to three PDX models of luminal B breast
cancer. Consistent with previous reports, PIK3CA mutation status alone did not accurately
predict outcome; WHIM18 and WHIM20 showed reduced tumor growth upon application of the
inhibitors, whereas WHIM16 did not (Figure 3.7d). mTOR inhibition repressed tumor growth in
WHIM18 and WHIM20 (ANOVA followed by Tukey's post hoc test, p = 9.5e-10, 1.6e-03
respectively), but not in WHIM16 (p = 0.97), showing that inhibition of mTORC1/2 may
effectively suppress breast tumors with activated AKTs and validating a previous study showing
the efficacy of mTOR inhibition in PDX models of triple-negative breast cancer100. Importantly,
the combinatorial treatment achieved the greatest effect in WHIM18 and WHIM20 (p < 2.2e-16
for both comparisons). While neither PI3K nor mTOR inhibitor drug treatment alone suppressed
tumor growth in WHIM20 completely, the combination of both PI3K and mTOR inhibitors
significantly reduced tumor growth to a nearly static state (Figure 3.7d). Based on our proteomic
characterization, WHIM20 exhibited the strongest AKT1 and AKT2 protein expression, as well
as AKT1 p.S122 and p.S475 phosphorylation signatures followed by WHIM18 and then
WHIM16 (Figure 3.6b, c). Further, both PI3K and mTOR inhibitors significantly reduced AKT
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p.S473 (Figure 3.7c). Our treatment results showed that the magnitude of drug response may be
associated with over-expression and phosphorylation of the downstream signaling targets such as
AKT proteins.

In addition to this validation of druggable hypotheses in luminal tumors, our previous report also
demonstrated the effectiveness of combinatorial therapy of AKT and mTOR inhibitors in two
other basal breast cancer xenografts101. One of the treated xenografts, WHIM4, was also
characterized in this study, and showed copy number amplification of PIK3CA and AKT3
protein outlier expression (Figure 3.6). Overall, proteogenomic analysis revealed that the dual
activation of PIK3CA at the genomic level and AKTs at the protein level may be a common
signature of breast tumors, affecting more than 20% of PDXs in this cohort. Importantly, our
results demonstrate the potential utility of combinatorial inhibitor treatments to treat breast
tumors showing these proteogenomic signatures.

3.3 Discussion

Breast cancer has been traditionally characterized in the clinic through hormone receptor status
and selected genes’ expressions86,102, and more recently by genomic sequencing13. However,
druggable genomic driver events are detectable in only a limited percentage of patients13. As the
majority of drugs target proteins, a systematic evaluation of breast cancer proteomes would seem
ultimately to be necessary for selecting targeted treatment and predicting drug response. Recent
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advances in MS-based proteomics allow extensive and quantitative surveys of the global
proteome. Here, we have systematically analyzed proteogenomic profiles of 22 patient-derived
breast cancer xenografts and 2 EBV-positive lymphoproliferations that are likely artifacts of
engraftment of human lymphocytes into NSG mice.
This study shows that proteogenomic signatures of PDXs resemble most findings from breast
cancer patients. While some discrepancies exist, we established a normalization strategy at both
the genomic and proteomic levels that enabled direct comparison. PDX tumors recapitulated the
proteomic diversity of human breast cancers (Figure 3.3). We also identified multiple druggable
targets for each tumor model (Figure 3.6). Proteomic events validated a significant number of
CNV or mRNA up-regulations. For example, HER2 protein and phosphosite outlier expression
was observed in HER2-E WHIM8 and WHIM35 (Figure 3.5), which were effectively treated
using lapatinib (Figure 3.7b). Interestingly, we also identified overexpressed proteomic events
not evident in the genomic level in both PDX and human samples, including outlier protein
expression of EGFR, and outlier phosphosite expressions of ARAF, BRAF, HSP90AB1,
PTPN11 and TOP2A (Figure 3.6), highlighting potential new treatment opportunities in breast
cancer. In the two PDX models subsequently diagnosed as EBV-positive lymphoproliferations,
we observed outlier BTK expression (Figure 3.6) and activation of the NFκB pathway (Figure
3.4), validating BTK as a druggable target in EBV+ lymphomas103. While more than 80% of the
proteomic outlier events in PDX were also found in human tumors, a lessor 48.8% of
phosphosite outlier events were validated, potentially due to different tumor micro-environments.
Thus, transient phosphoproteomic events identified in PDX tumors would likely require further
verification in their corresponding primary tumors.
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Outlier protein expression events can likely lead to downstream pathway activation, such as
MET outlier protein expression (Figure 3.6) and activated Ras pathway observed in WHIM12
(Figure 3.4). While genomic analysis has utilized mutual occurrence or exclusivity in patient
cohorts to deduce pathway relationships, phosphorylation profile analyses allowed us to directly
interrogate signaling in these established pathways in a single sample. Our pathway activation
results suggest these events may be crucial to tumorigenesis and that some are likely the
proteomic “smoking guns” that originally triggered the oncogeneic cascade.
Roughly 77% of breast tumors showed alterations in the PI3K-AKT signaling pathway,
representing a potentially important path forward for drug-based treatment. Yet, genomic
alterations of PI3K pathway components have not shown themselves to predict treatment
responsiveness to PI3K pathway inhibitors98. In this study, we defined complementary
druggable targets of the pathway using proteogenomic analysis, including several events of a cooccurring PIK3CA mutation or copy number amplification, and AKT protein outlier expression
coupled by elevated AKT phosphorylation. In two such breast tumors, we successfully inhibited
tumor growth using a combination of PI3K and MTOR inhibitors (Figure 3.7c). While these
results show potential functional implications, additional, systematic treatment experiments are
required to validate the identified proteomic druggable targets.
In conclusion, this initial work using proteogenomic integration coupled with patient-derived
xenograft validation, has demonstrated a strategy that, in principle, may enable more accurate
prediction of the efficacy of mechanism-based cancer therapeutics.
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3.4 Methods
Xenograft Model Generation
Patient-derived xenografts were generated from primary or metastatic breast tumors using
previously described procedures19. All human tissues for these experiments were processed in
compliance with NIH regulations and institutional guidelines, and approved by the institutional
review board at Washington University. All animal procedures were reviewed and approved by
the institutional animal care and use committee at Washington University in St. Louis. PDX
models are available through the application to the Human and Mouse-Linked Evaluation of
Tumors core at http://digitalcommons.wustl.edu/hamlet/.

We selected 24 of the established breast tumor samples, including 9 luminal B, 10 basal, 4
HER2-E, and 1 CLDN-low breast tumors for further proteogenomic characterization. Receptor
statuses of xenograft tumors were validated using IHC after engraftment.

Immunohistochemistry
Xenografts were formalin-fixed at least for 24 hours and paraffin-embedded. Sections were
evaluated by hematoxylin & eosin (H&E) staining. Immunohistochemistry (IHC) was performed
on additional sections for HER2 (Dako), Phospho-Akt (Ser473) (Cell signaling), FGFR2
(Abcam), and Raf-1 (Santa Cruz) following the manufacturer's instructions. Western blotting of
phosphorylated HER2 (p.Y1248) was performed using antibody cat Nr-06-229 (Millipore).

In-vivo Drug Treatment Experiments
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For the targeted treatment of the PI3K pathway, PI3K alpha inhibitor TAK-117 and TORC1/2
inhibitor TAK-228 were provided by Millennium Pharmaceuticals, Inc. The compounds were
dissolved in Peg400. Tumors were engrafted in NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice
(The Jackson Laboratory) by subcutaneous injection of 2-5 × 106 PDX cells in PBS
supplemented with 30% Matrigel (BD Biosciences Cat. No. 354234). When tumors reached an
average size of 250-300 mm3, animals were assigned randomly to control and various treatment
groups (n=8-9 each group). For treatment of WHIM16 (passage 7), 18 (passage 8), and 20
(passage 5) were used. Tumor bearing mice were gavaged with: 1) Peg400; 2) TAK-117, 140
mg/kg/day; 3) TAK-228, 1mg/kg/day; 4) TAK-117, 140 mg/kg/day, TAK-228, 1mg/kg/day. The
mice were treated on three consecutive days once daily and then had a 4-day interval. Tumors
were measured with external caliper, and volume was calculated as (4π/3) × (width/2)2 ×
(length/2).

For the lapatinib therapeutic experiments of WHIM6 (passage 7), WHIM 14 (passage 11),
WHIM 8 (passage 6) and WHIM 35 (passage 6), 1x106 tumor cells were added to equal volume
of 1:1 mixture of Matrigel and 10% RPMI plus 10% FBS to 4th mammary fat pads in female
SCID/bg mice (ENVIGO). We then established tumors to an average volume 250-300mm3, and
randomized the mice into control and lapatinib groups. We treated the treated group mice with
lapatinib chow diet by formulating lapatinib (220mg/kg) and processing them into food pellets
(by Research Diets Inc), which is supplied for 2 weeks. The numbers of replicates for each group
are as followed: WHIM 14 control (n=6) and lapatinib treated (n=5); WHIM 6 control (n=11)
and lapatinib treated (n=12); WHIM 8 control (n=16) and lapatinib treated (n=6); WHIM 35
control (n=17) and lapatinib treated (n=18). We also treated WHIM14 with 100mg/kg lapatinib
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treatment for 48 days, including both control (n=8) and lapatinib treated (n=9) groups. Further,
we tested the effect of trastuzumab (30mg/kg weekly with IP injections) and pertuzumab
(30mg/kg weekly with IP injections) on PDX tumor growth for 48 days. The experimental
groups are as following: control group (n=6) treated with physiological saline (vehicle);
trastuzumab treated group (n=12); pertuzumab treated group (n=11).

Statistical testing of the resulting data was conducted using the R programming language.
Wilcoxon rank sum test was applied to compare the fold change in tumor volumes after two
weeks in the lapatinib treatment experiment, and after 44 days or 48 days for the additional
WHIM14 experiment using low-dose lapatinib and trastuzumab/pertuzumab. One-way ANOVA
was applied to compare the treated vs. control groups in the PI3K targeted-therapy experiments,
and a follow-up Tukey’s post-hoc test was used for the various comparisons in PI3K inhibition
experiments. All human tissues for these experiments were processed in compliance with NIH
regulations and institutional guidelines, and approved by the Washington University, University
of North Carolina, or Baylor College of Medicine Institutional Review Board (IRB). All animal
procedures were reviewed and approved by the institutional animal care and use committee at
Washington University in St. Louis, University of North Carolina, or Baylor College of
Medicine.

Genomic and Proteomic Data Generation
Somatic Mutation
Sequencing reads were aligned using BWA104. Somatic variants were identified using
VarScan2105-107, GATK108, and Pindel109, and annotated based on Ensembl release 70_37. We
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then filtered out common variants by using variants from the 1000 Genomes and NHLBI
projects. We further eliminated mouse contamination by filtering somatic variants that were
mapped to mouse reference genome. Somatic mutation calls were validated either using a custom
array or manually reviewed in IGV. The genomic data of 17 out of the 24 PDXs have been
presented before in our previous studies16,110.
Copy Number Variation
The segment-based copy number data were generated using the whole-genome sequencing and
exome sequencing data. We then converted the segment-based copy number data to the genebased copy number data by using the RefSeq database (version 20130727). The copy number
values were further transformed to the log-R ratio, using the cohort mean for the gene as the
reference.

mRNA Expression and virus detection through RNA-Seq
mRNA expression values were calculated from mRNA sequencing data using MapSplice111,112.
The resulting RSEM values were normalized within samples to a fixed upper quartile. Upper
quartile normalized RSEM data were log2 transformed and the data were median centered by
gene. To quantify virus abundance, we used the VirusScan pipeline (https://github.com/dinglab/VirusScan) to detect viruses by numbers of virus-supporting reads from RNA-Seq data.

LFQ proteome
Tumor Sample Generation and Protein Extraction: Patient-derived xenograft breast tumors
were processed to cryopulverized powders as described previously113. The powders (100 mg wet
weight) were subjected to lysis and protein extraction using a buffer composed of 8 M urea, 50
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mM Tris pH 8.0, 75 mM NaCl, 1 mM MgCl2, and 500 units Benzonase. Approximately 1 mg of
total protein extracted was reduced with DTT and subsequently alkylated with iodoacetamide.
The proteins were then subjected to proteolysis with endoproteinase Lys-C (Wako Chemicals,
USA) for ~4 hours at 370C. The solution was diluted 4-fold with 25 mM Tris pH 8.0, 1 mM
CaCl2 and further digested with trypsin (Promega) for ~12 hours at 37 0C. Digestion was stopped
by the addition of TFA to 0.4%, and the precipitate was removed by centrifugation. The peptide
solutions were desalted on Sep-Pak Light C18 cartridges (Waters) and dissolved in 30% ACN,
0.1% TFA before loading on a 300 µm Source 15S (GE Healthcare) column for Basic Reversed
Phase Chromatography (bRPLC)49. A linear LC gradient was performed by increasing buffer B
from 0-70% within 60 min, where buffer A was aqueous 10 mM ammonium formate, and buffer
B was 90% ACN in 10 mM ammonium formate. A total of 30 fractions were collected for each
WHIM sample (18 WHIMs). Five fractions were then prepared by combining non-contiguously
fractions. We analyzed an additional technical replicate for WHIM2 and WHIM16. The fractions
were dried and desalted using a stop-and-go-extraction tip (StageTip) protocol containing 4 x 1
mm C18 extraction disk (3M).

Liquid Chromatography-Tandem Mass Spectrometry and Protein
Identification:
Sample analysis was performed via reversed phase LC-MS/MS using a Proxeon 1000 nano LC
system coupled to a Q Exactive mass spectrometer (Thermo Scientific, San Jose, CA). The
Proxeon system was configured to trap peptides using a C18 column (3 cm x 100 µm i.d.) with a
diverted flow rate (5 µL/min) The trap column was placed in line with the analytical column (15
cm x 75 µm i.d., 3.5 µm, 300 Å particle C18, Thermo Scientific, San Jose, CA) prior to gradient
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elution of peptides. Analytical separation of all the tryptic peptides was achieved with a linear
gradient of 2-30% buffer B over 240 min (250 nL/min), where buffer A was aqueous 0.1%
formic acid, and buffer B was acetonitrile in 0.1% formic acid.
LC-MS experiments were performed in a data-dependent mode with Full-MS (externally
calibrated to a mass accuracy of < 5 ppm, and a resolution of 70,000 at m/z = 200) followed by
HCD-MS/MS of the top 20 most intense ions. High-energy collision activated dissociation
(HCD)-MS/MS was used to fragment peptides at a normalized collision energy of 27 eV in the
presence of nitrogen. One LC-MS run was performed for each fraction (from 1 process technical
replicate), except for WHIM2 and WHIM16 where 2 LC-MS runs were conducted (from 3
process technical replicates), resulting in the production of 100 LC-MS runs for global peptide
analysis. Mass spectra were processed, and peptide identification was performed using the
Andromeda search engine found in MaxQuant software ver. 1.5.0.25. (Max Planck Institute,
Germany). All protein database searches were performed against the RefSeq database (version
20140707). Peptides were identified with a target-decoy approach using a combined database
consisting of reverse protein sequences of the RefSeq human, mouse and common repository of
adventitious proteins (cRAP). The cRAP database was obtained from the Global Proteome
Machine (ftp://ftp.thegpm.org/fasta/cRAP). Peptide inference was made with a false discovery
rate (FDR) of 1% while peptides were assigned to proteins with a protein FDR of 5%. A
precursor ion mass tolerance of 20 ppm was used for the first search that allowed for m/z
retention time recalibration of precursor ions that were then subjected to a main search using a
precursor ion mass tolerance of 6 ppm and a product ion mass tolerance 0.5 Da. Search
parameters included up to two missed cleavages at KR on the sequence, and oxidation of
methionine, and protein N-terminus acetylation as a dynamic modification.
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Carbamidomethylation of cysteine residues was considered as a static modification. Peptide
identifications are reported by filtering of reverse and contaminant entries and assigning to their
leading razor protein according to the Occams razor principal. The mass spectrometric data are
deposited at the CPTAC Data Coordinating Center as raw and mzML files (https://cptac-dataportal.georgetown.edu)114.

Peptide and Protein Quantitation: Label-free quantitation (LFQ) was performed based on peak
areas. The measured area under the curve of m/z and the retention time-aligned extracted ion
chromatograms of peptides were performed via the label-free quantitation module in MaxQuant
[ver. 1.5.0.25]115. All replicates for each PDX were included in the LFQ experimental design
with peptide-level quantitation performed using unique and razor peptide features corresponding
to identifications filtered with a posterior error probability (PEP) of 0.01, peptide FDR of 0.01
and protein FDR of 0.05. The expression values were median centered in the Perseus software
for further analysis [version 1.5.0.9].

iTRAQ proteome and phosphoproteome
We included all 24 of the established breast tumor samples for proteomic characterization using
iTRAQ. Tumor tissue samples were maintained in cryovials at -80°C until cryopulverization
using a CP02 Cryprep Pulverizer (Covaris, Woburn, MA). 90 mg aliquots of cryofractured
material were prepared for proteomic processing in aluminum weighing dishes on dry ice using
spatulas kept cold in liquid nitrogen, with remaining material reserved for other applications.
The 90 mg target was designed to include 40 mg for each of the collaborating research teams,
with an anticipated yield for each team of 1.5 – 2 mg protein based on 4-5% recovery. To avoid
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systematic bias, sample processing was block randomized, with each intrinsic subtype
proportionally represented in each processing tranche.
The reproducibility of the iTRAQ4-plex global proteome and phosphoproteome analysis
workflow used in this study has been extensively tested for quantitative reproducibility both
within and across laboratories in the CPTAC program83,116. Over a period of several months 5
iTRAQ4-plex replicates were measured at each of the 3 CPTAC proteome analysis centers. Each
of these iTRAQ4-plexes contained duplicate measurements for both a basal WHIM2 and a
luminal WHIM16 PDX samples that are also part of this study. A high degree of consistency in
the number of proteins identified and correlation in the protein expression was obtained116.
Pearson correlations for replicate proteome and phosphoproteome measurements were very high
with a r=0.9 in our previous study83 and very similar to the correlation observed here for the
WHIM13 replicate measurement. These data show that our platform provides highly
reproducible quantitative measurements for global proteomes and phosphoproteomes.

Protein extraction, digestion and iTRAQ labeling of peptides from breast cancer tumors:
Cryopulverized breast cancer tumor samples tissues (~2 combined aliquots of 90 mg tissue
weight each) were homogenized in 1000 µL lysis buffer containing 8M urea, 75mM NaCl, 1mM
EDTA in 50mM Tris HCl (pH 8), 10 mM NaF, phosphatase inhibitor cocktail 2 (1:100; Sigma,
P5726) and cocktail 3 (1:100; Sigma, P0044), 2 µg/mL aprotinin (Sigma, A6103), 10 µg/mL
Leupeptin (Roche, #11017101001), and 1 mM PMSF (Sigma, 78830). Lysates were centrifuged
at 20,000 g for 10 minutes before measuring protein concentration of the clarified lysates by
BCA assay (Pierce). Protein lysates were subsequently reduced with 5 mM dithiothreitol
(Thermo Scientific, 20291) for 45 minutes at room temperature, and alkylated with 10 mM
86

iodoacetamide (Sigma, A3221) for 45 minutes in the dark. Samples were diluted 4-fold with
50mM Tris HCl (pH 8) prior to digesting them with LysC (Wako, 129-02541) for 4 hours and
trypsin (Promega, V511X) overnight at a 1:50 enzyme-to-protein ratio at room temperature
overnight on a shaker.
Digested samples were acidified with formic acid (FA; Fluka, 56302) to a final volumetric
concentration of 1 % or final pH of ~3-5, and centrifuged at 2,000 g for 5 minutes to clear
precipitated urea from peptide lysates. Samples were desalted on C18 SepPak columns (Waters,
100mg, WAT036820) and 1mg peptide aliquots were dried down using a SpeedVac apparatus.

Construction of the Common internal Reference Pool: The proteomic and phosphoproteomic
analyses of xenograft samples were performed as iTRAQ 4-plex experiments. Quantitative
comparison between all samples analyzed was facilitated by the use of iTRAQ reporter ion ratios
between each individual sample and a common internal reference sample present in each 4-plex.
The reference sample was comprised of 16 of the 24 WHIM tumors analyzed in this study with
equal contribution for each tumor (WHIM numbers 2, 4, 6, 8, 11, 12, 13, 14, 16, 18, 20, 21, 24,
25, 30, and 46). The 24 tumor samples were analyzed in 9 independent 4-plex experiments, with
3 individual samples occupying the first 3 channels of each experiment and the 4th channel being
reserved for the reference sample. While 8 iTRAQ 4-plex experiments were used to analyze the
24 individual WHIM tumor samples, an additional 4-plex experiment was designed to include
the WHIM13 sample for process replicate analysis and also internal reference samples from our
human primary breast cancer study83 and a taxol drug response study (unpublished) to allow
cross-referencing of the different datasets.
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iTRAQ labeling, high pH reversed-phase separation and phosphopeptide enrichment of
peptide samples: Desalted peptides were labeled with 4-plex iTRAQ reagents according to the
manufacturer’s instructions (AB Sciex, Foster City, CA). For each 1 mg peptide from each breast
tumor sample, 10 units of labeling reagent were used. Peptides were dissolved in 300 µL of 0.5
M triethylammonium bicarbonate (TEAB) (pH 8.5) solution and labeling reagent was added in
700 µL of ethanol. After 1 h incubation, 1.5 mL of 0.05% TFA was added to stop the reaction.
Differentially labeled peptides were mixed and subsequently desalted on 500 mg tC18 SepPak
columns. The combined 4 mg iTRAQ samples per experiment were separated into 24 proteome
fractions and 12 phosphoproteome fractions using a 4.6mm x 250mm column RP Zorbax 300 A
ExtendC18 column (Agilent, 3.5 µm bead size) on an Agilent 1100 Series HPLC instrument by
basic reversed-phase chromatography as described previously113. Peptides were separated
according to their hydrophobicity using solvent A (2% acetonitrile, 5 mM ammonium formate,
pH 10) and a nonlinear increasing concentration of solvent B (90% acetonitrile, 5 mM
ammonium formate, pH 10). Phosphopeptides were enriched using Ni-NTA superflow agarose
beads (Qiagen, #1018611) that were stripped of nickel with 100 mM EDTA and incubated in an
aqueous solution of 10 mM FeCl3 (Sigma, 451649) as described previously117. For
phosphopeptide enrichment a 80% acetonitrile/0.1% trifluoroacetic acid binding buffer and a 500
mM dibasic sodium phosphate, pH 7.0, (Sigma, S9763) elution buffer were used. Enriched
samples were desalted on StageTips as described117 before analysis by LC-MS/MS.

Analysis of tumor samples by high performance liquid chromatography tandem mass
spectrometry (LC-MS/MS): All peptides were separated with an online nanoflow Proxeon
EASY-nLC 1000 UHPLC system (Thermo Fisher Scientific) and analyzed on a benchtop
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Orbitrap Q Exactive mass spectrometer (Thermo Fisher Scientific) equipped with a nanoflow
ionization source (James A. Hill Instrument Services, Arlington, MA). The LC system, column,
and platinum wire to deliver electrospray source voltage were connected via a stainless-steel
cross (360µm, IDEX Health & Science, UH-906x). The column was heated to 50oC using a
column heater sleeve (Phoenix-ST) to prevent overpressurizing of columns during UHPLC
separation.10% of each global proteome sample in a 2 ul injection volume, or 50% of each
phosphoproteome sample in a 4 ul injection volume was injected onto an in-house packed 20cm
x 75um diameter C18 silica picofrit capillary column (1.9 µm ReproSil-Pur C18-AQ beads, Dr.
Maisch GmbH, r119.aq; Picofrit 10um tip opening, New Objective, PF360-75-10-N-5). Mobile
phase flow rate was 200nL/min, comprised of 3% acetonitrile/0.1% formic acid (Solvent A) and
90% acetonitrile /0.1% formic acid (Solvent B), and the 110-minute LC-MS/MS method
consisted of a 10-min column-equilibration procedure, a 20-min sample-loading procedure, and
the following gradient profile: (min:%B) 0:2; 1:6; 85:30; 94:60; 95;90; 100:90; 101:50; 110:50
(last two steps at 500 nL/min flowrate). Data-dependent acquisition was performed using
Xcalibur QExactive v2.1 software in positive ion mode at a spray voltage of 2.00 kV. MS1
Spectra were measured with a resolution of 70,000, an AGC target of 3e6 and a mass range from
300 to 1800 m/z. Up to 12 MS2 spectra per duty cycle were triggered at a resolution of 17,500,
an AGC target of 5e4, an isolation window of 2.5 m/z, a maximum ion time of 120 msec, and a
normalized collision energy of 28. Peptides that triggered MS2 scans were dynamically excluded
from further MS2 scans for 20 sec. Charge state screening was enabled to reject precursor charge
states that were unassigned, 1, or >6. Peptide match was enabled for monoisotopic precursor
mass assignment.
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Protein-peptide identification, phosphosite localization, and quantitation: All MS data were
interpreted using the Spectrum Mill software package v5.1 (for comparison with proteomes of
human breast tumors from our previous study83) and v6.0 pre-release (Agilent Technologies,
Santa Clara, CA) co-developed by the authors. Similar MS/MS spectra acquired on the same
precursor m/z within +/- 45 sec were merged. MS/MS spectra were excluded from searching if
they failed the quality filter by not having a sequence tag length > 0 (i.e., minimum of two
masses separated by the in-chain mass of an amino acid) or did not have a precursor MH+ in the
range of 750-6000. MS/MS spectra from were searched against a database consisting of RefSeq
release 60 containing 31,767 human proteins, 24,821 mouse proteins, and an appended set of 85
common laboratory contaminant proteins (RefSeq.20130727-Human.20130730MouseNR.mm13.contams). Scoring parameters were ESI-QEXACTIVE-HCD-v2, for whole
proteome datasets, and ESI-QEXACTIVE-HCD-v3 parameters were for phosphoproteome
datasets. All spectra were allowed +/- 20 ppm mass tolerance for precursor and product ions,
40% minimum matched peak intensity, and trypsin allow P enzyme specificity with up to 4
missed cleavages. Fixed modifications were carbamidomethylation at cysteine. iTRAQ labeling
was required at lysine, but peptide N-termini were allowed to be either labeled or unlabeled.
Allowed variable modifications for whole proteome datasets were acetylation of protein Ntermini, oxidized methionine, deamidation of asparagine, pyro-glutamic acid at peptide Nterminal glutamine, and pyro-carbamidomethylation at peptide N-terminal cysteine with a
precursor MH+ shift range of -18 to 64 Da. Allowed variable modifications for
phosphoproteome dataset were revised to disallow deamidation and allow phosphorylation of
serine, threonine, and tyrosine with a precursor MH+ shift range of 0 to 272 Da.
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Identities interpreted for individual spectra were automatically designated as confidently
assigned using the Spectrum Mill autovalidation module to use target-decoy based falsediscovery rate (FDR) estimates to apply score threshold criteria via two-step strategies. For the
whole proteome datasets thresholding was done at the spectral and protein levels. For the
phosphoproteome datasets thresholding was done at the spectral level. In step 1, peptide
autovalidation was done first and separately for each iTRAQ 4-plex experiment consisting of
either 25 LC-MS/MS runs (whole proteome) or 13 LC-MS/MS runs (phosphoproteome) using an
auto thresholds strategy with a minimum sequence length of 7(whole proteome) or 8
(phosphoproteome), automatic variable range precursor mass filtering, and score and delta
Rank1 – Rank2 score thresholds optimized to yield a spectral level FDR estimate for precursor
charges 2 thru 4 of <0.6% for each precursor charge state in each LC-MS/MS run. For precursor
charges 5-6, thresholds were optimized to yield a spectral level FDR estimate of <0.3 % across
all runs per iTRAQ 4-plex experiment (instead of each run), to achieve reasonable statistics,
since many fewer spectra are generated for the higher charge states.

In step 2 for the whole proteome datasets, protein polishing autovalidation was applied
separately to each iTRAQ 4-plex experiment to further filter the PSM’s using a target proteinlevel FDR threshold of zero. The primary goal of this step was to eliminate peptides identified
with low scoring peptide spectrum matches (PSM’s) that represent proteins identified by a single
peptide, so-called “one-hit wonders”. After assembling protein groups from the autovalidated
PSM’s, protein polishing determined the maximum protein level score of a protein group that
consisted entirely of distinct peptides estimated to be false-positive identifications (PSM’s with
negative delta forward-reverse scores). PSM’s were removed from the set obtained in the initial
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peptide-level autovalidation step if they contributed to protein groups that have protein scores
below the max false-positive protein score. In the filtered results each identified protein detected
in an iTRAQ 4-plex experiment was comprised of multiple peptides unless a single excellent
scoring peptide was the sole match. For the whole proteome datasets the above criteria yielded
false discovery rates (FDR) of <0.5% at the peptide-spectrum match level and <0.8% at the
distinct peptide level for each iTRAQ 4-plex experiment. After assembling proteins with all the
PSMs from all the iTRAQ 4-plex experiments together the aggregate FDR estimates were 0.42%
at the at the peptide-spectrum match level, 1.5% at the distinct peptide level, and <0.01%
(1/11,372) at the protein group level. Since the protein level FDR estimate neither explicitly
required a minimum number of distinct peptides per protein nor adjusted for the number of
possible tryptic peptides per protein, it may underestimate false positive protein identifications
for large proteins observed only on the basis of multiple low scoring PSMs.

In calculating scores at the protein level and reporting the identified proteins, redundancy was
addressed in the following manner: the protein score was the sum of the scores of distinct
peptides. A distinct peptide was the single highest scoring instance of a peptide detected through
an MS/MS spectrum. MS/MS spectra for a particular peptide may have been recorded multiple
times, (i.e. as different precursor charge states, in adjacent bRP fractions, modified by
deamidation at Asn or oxidation of Met, or different phosphosite localization) but were still
counted as a single distinct peptide. When a peptide sequence >8 residues long was contained in
multiple protein entries in the sequence database, the proteins were grouped together and the
highest scoring one and its accession number were reported. In some cases when the protein
sequences were grouped in this manner there were distinct peptides that uniquely represented a
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lower scoring member of the group (isoforms, family members, and different species). Each of
these instances spawned a subgroup. Multiple subgroups were reported and counted towards the
total number of proteins, and were given related protein subgroup numbers (e.g. 3.1 and 3.2:
group 3, subgroups 1 and 2). To better dissect the tumor/stroma (human/mouse) origin of
orthologous proteins in this xenograft experiment, the inclusion of peptides contributing to each
subgroup was restricted by enabling the subgroup-specific (SGS) option in Spectrum Mill. Only
subgroup-specific peptide sequences were counted toward each subgroup’s count of distinct
peptides and protein level TMT quantitation. The SGS option omits peptides that are shared
between subgroups. If evidence for BOTH human and mouse peptides from an orthologous
protein were observed, then peptides that can not distinguish the two (shared) were ignored.
However, the peptides shared between species were retained if there was specific evidence for
only one of the species, thus yielding a single subgroup attributed to only the single species
consistent with the specific peptides. Furthermore, if all peptides observed for a protein group
were shared between species, thus yielding a single subgroup composed of indistinguishable
species, then all peptides were retained. Assembly of confidently identified PSM’s yielded
20,480 total protein subgroups from 11,372 protein groups. Human and mouse ortholog proteins
were typically arranged into individual subgroups.

In step 2 for the phosphoproteome datasets a phosphosite table were assembled with columns for
individual iTRAQ 4-plex experiments and rows for individual phosphosites. PSM’s were
combined into a single row for all non-conflicting observations of a particular phosphosite. (i.e.
different missed cleavage forms, different precursor charges, confident and ambiguous
localizations, different sample handling modifications). For related peptides neither observations
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with a different number of phosphosites nor different confident localizations were allowed to be
combined. Selecting the representative peptide from the combined observations was done such
that once confident phosphosite localization was established, higher identification scores and
longer peptide lengths are preferable. After assembling the phosphosite table a polishing step
was applied to further filter the phosphosites with the primary goal of eliminating phosphosites
with representative peptides identified through low scoring peptide spectrum matches (PSM’s)
that were observed in only a few experiments. The initial table of representative peptides for
82,030 phosphosites had an aggregate FDR of 3.3% at phosphosite-level. The table was sorted
by identification score and then by number of iTRAQ 4-plex experiments in which the
phosphosite was observed. The cumulative FDR trend showed inflection points at an
identification score of ~8. Phosphosites with an identification score < 8.0 observed in <3/9
experiments were therefore removed, yielding 68,385 phosphosites with an aggregate FDR of
0.34% at the phosphosite level. While the Spectrum Mill identification score is based on the
number of matching peaks, their ion type assignment, and the relative height of unmatched
peaks, the phosphosite localization score is the difference in identification score between the top
two localizations. The score threshold for confident localization (>1.1) essentially corresponds to
at least 1 b or y ion located between two candidate sites that has a peak height 10% of the tallest
fragment ion (neutral losses of phosphate from the precursor and related ions as well as
immonium and iTRAQ reporter ions are excluded from the relative height calculation). The ion
type scores for b-H3PO4, y-H3PO4, b-H2O, and y-H2O ion types are all set to 0.5. This prevents
inappropriate confident localization assignment when a spectrum lacks primary b or y ions
between two possible sites but contains ions that can be assigned as either phosphate loss ions for

94

one localization or water loss ions for another localization. In aggregate, 66.3% of the reported
phosphosites were fully localized to a particular serine, threonine, or tyrosine residue.

Relative abundances of proteins and phosphosites were determined in Spectrum Mill using
iTRAQ reporter ion intensity ratios from each PSM. A protein-level or phosphosite-level iTRAQ
ratio was calculated as the median of all PSM level ratios contributing to a protein subgroup or
phosphosite remaining after excluding those PSM’s lacking an iTRAQ label, having a negative
delta forward-reverse score (half of all false-positive identifications), or having a precursor ion
purity < 50% (MS/MS has significant precursor isolation contamination from co-eluting
peptides). Unless stated otherwise for a particular analysis, the following considerations apply to
the tumor/stroma (human/mouse) origin of a protein in this xenograft experiment. For the
proteome dataset, only PSM’s from subgroup-specific peptide sequences contributed to the
protein level quantitation (see protein subgrouping description above). A protein detected with
all contributing PSM’s shared between human and mouse was considered to be human. For the
phosphoproteome dataset, a phosphosite was considered to be mouse if the contributing PSM’s
were distinctly mouse and human if they were either distinctly human or shared between human
and mouse. A 2-component Gaussian mixture model-based normalization approach was used to
center the distribution of iTRAQ log-ratios around zero in order to nullify the effect of
differential protein loading and/or systematic MS variation83. Downstream analyses presented in
the main figures were restricted to proteins/phosphosites quantified in at least 10 out of the 24
samples with non-missing values, with the exception of the previously described mRNA-protein
correlation analysis28 requiring quantification in 30%, or 8 out of 24, PDX samples. Specific
filtering procedures are noted in descriptions of the relevant methods.
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Bioinformatics analyses

Cross data-type integration
All gene names were converted to HUGO Gene Nomenclature Committee’s approved gene
names for comparison across levels and datasets. For mRNA and protein expressions, expression
values were collapsed across transcripts or isoforms to the corresponding gene using the highest
mean when there were two transcripts or isoforms, or the value with the highest connectivity
when there were more than three transcripts or isoforms as implemented in the WGCNA R
package118.

mRNA-protein correlation
Spearman correlations between normalized RSEM values and protein quantifications were
calculated for genes that were observed in at least 30% of samples for both RNA-seq and massspectrometry as previously described. KEGG pathway enrichment analysis of the correlation was
carried out using a Kolmogorov-Smirnov test, and P values were adjusted using the BenjaminiHochberg procedure.

Proteomic clustering and subtyping
We first applied filtering for protein and phosphosite markers observed in at least 10 samples and
sufficient deviations across samples. We used a 2 standard deviation threshold for iTRAQ
proteome and 2.5 standard deviation for the phosphoproteome. We applied the same protein
marker to conduct LFQ proteome and PDX vs. human proteome co-clustering. For the co96

clustering with human proteome, we further selected for markers that had higher than 2 standard
deviations in the merged proteome and showed non-differential expression between human and
PDX (FDR > 0.3, t-test). The subsequent hierarchical clustering was conducted using the
complete agglomeration method of hclust as implemented in the heatmap2 R package.

Differential expression analysis
Differential expression testing of each protein in the LFQ and iTRAQ datasets was conducted
using the student’s t-test, and P values were adjusted using the Benjamini-Hochberg procedure.
For gene set enrichment analysis, we conducted the Wilcoxon Rank Sum Test to test for changes
in the t-statistics ranks of protein members in each of the KEGG signaling pathway, and again
adjusted p values using the Benjamini-Hochberg procedure.

Druggable genes and mutations
We compiled a list of druggable genes based on extensive curation of public databases:
Tumor Alterations Relevant for GEnomics-driven Therapy (TARGET, version 3, assessed on
6/15/2015), Personalized Cancer Therapy (PCT, assessed on 3/15/2015), GDKD (Gene-Drug
Knowledge Database, version 11.0, assessed on 4/10/2015), CancerDR (assessed on 2/6/2015),
My Cancer Genome (assessed on 9/11/2014), and DrugBank (assessed on 9/21/2015). We
curated the list based on evidence level and literature, as well as IC50 data when available. The
final list used for the analysis included 76 druggable genes.

Druggable outlier analysis
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To discover expression outliers, we utilized a strategy incorporating multiple steps: first, we
limited our search to genes that are in the druggable gene list. We then narrowed down the list to
genes that are observed in at least 10 samples in the dataset under investigation. Outlier
expressions were defined as values that are greater than 1.5 interquartile ranges (IQRs) above the
third quartile (Q3). To rank order outlier expression for each gene, we calculated an outlier score
defined as:
Outlier score = (x –Q3)/IQR
By definition, genes with outlier score greater than 1.5 are considered as expression outliers.
Outlier score for each gene were ranked within the sample to select the most promising
druggable targets. For CNV outliers, we required them to have outlier scores above 1 in at least
another expression level. For validation of the proteomic druggable outliers, we counted the
numbers of the same protein or phosphosite outliers observed in the parallel-processed cohort of
77 human breast cancer samples. Due to the lower numbers in this larger cohort, we considered
both proteins with outlier score greater than 1 and the top 2 outliers of each human sample as
validating outliers.

Pathway activation analysis
We first collapsed the phosphosites to gene-level phosphorylation values by averaging the
phosphosite expressions observed for each gene. Then, we converted the phosphoproteomic
expression values from iTRAQ to modified z-scores normalized against the cohort as described
in Hoaglin et al. (How to Detect and Handle Outliers). We then used the Wilcoxon Rank Sum
Test to test for changes in the phosphorylation z-score ranks of protein members in each of the
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KEGG signaling pathway. The resulting P values were adjusted using the Benjamini-Hochberg
procedure.
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Chapter 4: Redefine druggable targets in
breast cancer by global phospho-proteomics

4.1 Abstract

Aberrant phospho-signaling is a hallmark of cancer. We investigated kinase-substrate regulation
of 33,239 phosphorylation sites (phosphosites) in 77 breast tumors followed by validation in 24
xenografts. Our search discovered 19,521 novel phosphosites and 2,134 total correlated kinasephosphosite pairs. Among the 91 kinases with auto-phosphorylation, elevated EGFR,
ERBB2/MAP3K5, PRKG1, and WNK1 regulations were enriched in basal, HER2-E, Luminal A,
and Luminal B breast cancers, respectively, revealing subtype-specific signaling. CDKs,
MAPKs, and ataxia-telangiectasia proteins were dominant, master regulators of substratephosphorylation whose activities are not captured by genomic evidence. We unveiled activated
phospho-signaling, prioritizing targets from 113 activated kinase-substrate pairs and cascades
downstream of kinases including AKT1, BRAF and EGFR. We further identified kinasesubstrate-pairs associated with clinical biomarkers and phosphoproteomic immune signatures.
Overall, kinase-substrate regulation revealed by the largest unbiased global phosphorylation data
to date connects driver events to their signaling effects and potentially inform rational targeted
treatment of individual breast tumors.
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4.2 Results
Catalog of phosphosites in breast cancer

Figure 4.1. Landscape of the 33,239 quantified phosphosites in breast cancer. (a)
Distribution of phosphosites and counts of serine (S), threonine (T), and tyrosine (Y) residues
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regulated phosphosites that are novel (left) and previously known (right).

characterized by TCGA119 and CPTAC23 (Figure 4.1, Methods). Genomic analysis of TCGA
DNA-Seq, SNP-array and RNA-Seq data provided comprehensive assessment of somatic
mutations, copy number variations (CNV), and mRNA expression, respectively. The CPTAC
breast cancer project quantified global protein and phosphosite expression levels using the
Isobaric Tag for Relative and Absolute Quantitation (iTRAQ) technology. We further utilized
proteogenomic data from 24 independent breast cancer patient-derived xenografts (PDXs) 120
generated using the same technologies and pipeline for validation.

As previously described83, 33,239 out of the 62,679 confidently identified phosphosites passed
additional missing value and standard deviation filter and were used for downstream analyses
(Methods). This catalog of breast cancer phosphosites added 19,521 novel phosphosites when
compared to the 12,952 and 24,911 genomically-mapped human phosphosites of the UniProt and
the Phospho.ELM database121 (Figure 4.1a,b). These phosphosites covered 315 out of the 523
previously described human kinases122,123. Kinases with a significant number of novel
phosphosites may have an underappreciated regulatory role in breast cancer, including MAST2
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(30 novel phosphosites) and MAST4 (26) from the AGC kinase group, CDK13 (22) and CDK12
(11) from the CMGC kinase group, SLK (22) and MAP4K4 (18) from the STE kinase group, and
ERBB2 (10) from the TK group (Figure 4.1c). Compared to other quantified sites, the 84
detected, known cancer-associated phosphosites (Methods), including AKT1 p.T308, GSK3B
p.S9 and MTOR p.S2448, exhibited higher standard deviation in both breast cancer and PDX
samples (Wilcoxon rank sum test, p = 0.002567 and 0.0002608, respectively).

In this study, we aim to identify correlated kinase-substrate pairs that are concordant in their
relative abundance across samples (Figure 4.1d). We hypothesize these phosphosites are
regulated in a patient-specific manner, contributing to cross-sample variation in wiring of
signaling networks. We examined two classes of kinase-substrate relations: (1) cis interactions
whereby a kinase protein expression is correlated with its own phosphosites and (2) trans
interactions whereby a kinase phosphoprotein expression is correlated with a substrate
phosphosite level (Methods). To achieve this we curated and screened 4,997 pairs of human
kinase and substrate proteins based on the PhosphositePlus and PhosphoNetwork databases124,125.
806 novel and 848 previously identified phosphosites are identified as regulated: 324 by cisregulation, 1,271 by trans-regulation and 59 by both interactions (Figure 4.1e).
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Phosphosites in auto-phosphorylated kinases

Figure 4.2. Regulated cis kinase-phosphosite pairs. (a) Volcano plots highlighting
positively cis-regulated pairs. Regulations that were validated in the 24 PDX models (P <
0.05) are colored in red. (b) Counts of cis-regulated phosphosites among all corresponding
phosphosites for each kinase. Kinases with more than 7 cis-regulated phosphosites are shown
individually in a close-up barplot (right). (c) Top associated cis pairs and their average kinase
protein and phosphosite levels in each of the breast cancer subtypes. On the left panel, each
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dot represents a cis association identified by the regression analysis, where its size represen
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PAK2 and PRS6KA4 and their respective top 3 cis-regulated phosphosites. Each dot
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represents one tumor sample colored according to its subtype.

phosphorylation were evaluated with relation to peptide abundance of their 630 phosphosites
using a linear regression model (Methods). Protein abundance measures do not always guarantee
the activation of the phosphosites of the same protein: 61.4% (387/630) of the tested kinasesubstrate relations showed significant positive associations (regression coefficient b > 0 and FDR
< 0.05) in breast cancer (Figure 4.2a). Out of the 387 cis-regulated sites, 348 (89.9%) are novel
kinase target sites absent in PhosphositePlus. These novel cis-regulated sites are in 98 unique
kinases including ERBB2, EGFR and MAP3K5. Of the identified cis-regulatory pairs, 98.4%
with sufficient PDX data (179/182) showed positive correlation (b > 0.1) in the cohort of 24
breast cancer PDXs120 and were validated. The AGC kinase group was most significantly
enriched with cis associations (Fisher’s Exact Test, P = 0.0241, Methods) with all 17 tested
genes showing significant cis correlations with its phosphosites, followed by the STE group
(14/14 genes, P = 0.0487). Notably, at the kinase family level, we observed significant cisregulation in all 8 of the STE20 kinases included in the analysis including PAK1/2/4, STK3/4/24
and MAP4K1/3.

Top proteins with high percentage of cis-regulated phosphosites (Figure 4.2b) included wellknown and novel breast cancer associated-proteins such as ERBB2 (15 significant cis-regulated
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phosphosites), RPS6KA4 (15), NEK9 (11), RIPK2 (11), CDC42BPA (10) and GTF2F1 (10).
Further, at least 7 cis-regulated phosphosites in each of ERBB2, PAK4, NEK9, and RIPK2 were
validated in the PDX cohort (b > 0.1). Various cis-regulations exhibited molecular distinctions
across breast cancer subtypes (Figure 4.2c), exemplified by elevated ERBB2 protein and
phosphorylation in HER2-E breast cancers. Other subtype-specific regulated pairs identified
were WNK1 up-regulated in luminal A, and EGFR and SRPK1 up-regulated in basal breast
cancers. Closer examination revealed clear correlations between levels of PAK2 protein and its
p.T143 and p.S2 phosphosites as well as PRS6KA4 protein and its p.S681 and p.S682
phosphosites (Figure 4.2d).

We hypothesized that the observed cis associations were mainly due to two mechanisms: (1) A
higher protein level directly increases the abundance phosphorylation site level, where each unit
change in kinase expression would result in an equally proportional change in phosphosite level,
and (2) The kinase autophosphorylates itself, where each unit change in kinase protein may
result in a higher unit change in phosphosite level. We identified 41 cis-regulated sites that may
be affected by auto-phosphorylation using this criterion (b > 1), including CDK9 p.T186, RAF1
p.S43, BRAF p.S151/S729 and PRS6KA4 p.S737.

Kinase-substrate interactions
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Figure 4.3. Regulated trans kinase-substrate phosphosite pairs. (a) Volcano plots
highlighting positively regulated pairs. Regulations that were validated in PDX models (P <
0.05) are colored in red. (b) Counts of trans-regulated phosphosites among all corresponding
phosphosites for each kinase. Kinases with more than 30 trans-regulated phosphosites are
shown individually in a close-up barplot (right). (c) Top associated trans pairs and their
average kinase phosphoprotein and substrate phosphosite levels in each of the breast cancer
subtypes. On the left panel, each dot represents a trans association identified by the
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kinase-substrate phosphosite relations with sufficient observations in our data set (Methods). We
applied a linear model using phosphosite abundance of the substrate as the dependent variable
and phosphoprotein expression of the kinase as the independent variable and the protein
expression of the substrate as a covariate. Only 4.51% (1,747/38,710) of the tested relations
showed significant positive associations (Figure 4.3a). Among the 1287 trans-regulatory pairs
based on kinase-substrate relations of PhosphositePlus, 1117 (86.8%) are novel sites absent in
the existing databases. A significant fraction (45.8%) of these novel sites are regulated by CDKs,
MAPKs, ATR, and ATM. Of the identified trans-regulatory pairs, 45.5% with sufficient PDX
data (407/894) were confirmed (b > 0.1) in breast cancer PDXs120. The moderate validation rate
may be due to increased sensitivity to micro-environment in trans pairs and larger sample sizes
may be required to firmly establish trans associations. The identified trans-regulations are
congregated in 165 kinases, which showed the most significant enrichment in MAPK (P =
0.000448), CDK (P = 0.00259), and PKC (P = 0.00613) families.

Multiple kinases with the highest number of trans associations have been previously implicated
in breast cancer. Particularly, ATM (33 trans-regulated substrate phosphosites) and ATR (44),
proteins known to orchestrate the DNA damage response (DDR) pathway, were significantly
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associated with phosphosites of chromatin-associated SMARCC2, MCM2, histone-lysine
methyltransferase KMT2A and the DNA damage checkpoint protein TP53BP1. In the PI3K
pathway, kinases associated with trans-regulations of more than 20 phosphosites included
GSK3B (35), RPS6KB1 (39), MTOR (29) and RPS6KA1 (21). We also observed specific
interactions such as the inhibitory phosphorylation of GSK3A by AKT1 (AKT1:GSK3A p.S278,
FDR = 0.0341)126.

CDK1 (178 trans-regulated phosphosites), CDK2 (72) and CDK7 (44) showed a wide-spread
effect of trans-regulations on substrates including NUP98 and FLNA, supporting their central
roles in cell cycle signaling. MAPK1 (148 trans-regulated phosphosites), MAPK3 (111),
MAPK8 (50), MAPK14 (18) and MAPK9 (15) were also associated with up-regulation of
phosphosites of multiple downstream substrates including RPS6KA3/5, GAB1/2, MAP2K1, and
CIC (Figure 4.3c,d).
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Sequence and structural patterns of phosphosites
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Our cis and trans
analyses identified
pairs of
phosphosites on
the same protein
showing
concordant
regulation
patterns, including
those in ERBB2,
PRKCB, and
WNK1. We
hypothesized that
phosphosites in
spatial proximity
would be affected
by the same
regulators and
show similar
phosphorylation

Figure 4.4. Patterns of regulated phosphosites on primary sequences and 3D structur
(a) Consistent cis-regulations of phosphosites idenfied in ERBB2. (b) Discordant cis-

regulations of phosphosites identified in AKT1. (c) Cis and trans-regulations by MAPK3 o

RAF1 phosphosites. (d) Cis-regulated phosphosites p.T202 and p.Y204 in spatial proximit
adjacent to the active site p.D166 of MAPK3 as in PDB structure 4QTB 127. (e) Trans-

regulated phosphosites p.S201 and p.S207 (by MAP3K5) are found in spatial proximity to

the active sites, including p.D179 and p.T211, of MAP2K6, which is co-crystalized with an
ATP analog as in PDB structure 3VN9 128.

patterns. For each pair of phosphosites, we calculated the correlation coefficient of their levels
and compared that to their distances on PDB structures as determined by HotSpot3D74,126
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(Methods). We found a significant association between the correlation of phosphosite levels and
3D distances of the phosphosite pairs (Spearman correlation, P = 3.514e-08), and linear distances
(P = 0.000793), confirming co-regulation in adjacent phosphosites.

Phosphosites with strong cis-regulations may help detect activating events correlated with high
kinase expression. We identified ERBB2 p.S1151/S998/T1240 showing the most significant cisregulations (b > 0.65; FDR < 6.24E-16) and may serve as complementary HER2 biomarkers to
the tyrosine residues targeted by available antibodies, such as p.Y1221 and p.Y1248 (Figure
4.4a). On the other hand, poorly correlated phosphosites in kinases with strong cis-effects may
suggest additional post-translational modification mechanisms. For example, we observed strong
association between AKT1 protein and phosphorylation levels for sites p.S122/S126/S129 (FDR
< 8.22E-08). However, the associations for p.T308/S475 (FDR > 0.378) are considerably weaker
even with similar observed sample sizes (Figure 4.4b). Other discordant sites include the
strongly associated ABL1 p.S637/S737/T800/T871 vs. the non-associated p.S16/S588/S828; the
strongly associated PTK2 p.S390/S570/S708/S910 vs. the non-associated p.Y576/S840; and the
associated RIPK1 p.S320/S610 vs. the non-associated p.S330/S416.

In RAF1, we observed strong cis-regulations at p.S43/T260/S233/S220 (FDR < 0.0358), but not
p.S29 (FDR = 0.835, Figure 4.4c). This association pattern is complemented by the transregulation of RAF1 by MAPK3: RAF1 p.S29/T241 are tightly correlated with MAPK3
phosphoprotein expression (FDR < 0.0320) when controlled for RAF1 protein expression,
indicating MAPK3 may specifically regulate RAF1 phosphorylation at these sites via a feedback
loop.
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Intriguingly, several regulated phosphosites reside in structural proximity to active sites of
kinases. MAPK3 (ERK1) p.T202/Y204, which are known to be phosphorylated by MAP2K1 and
MAP2K2 (MEK1 and MEK2) to trigger its activation129,130, are adjacent to its active site p.D166
(Figure 4.4d). These two sites showed significant cis-regulation by MAPK3 protein albeit not
trans-regulation by MAP2K1/2 phosphoprotein. In MAP2K6, MAP3K5-regulated p.S207 and an
adjacent site p.S201 are located in its catalytic domain near active sites p.D179 and p.T211
(Figure 4.4e). These phosphosites may alter the biochemical properties of the active site and
affect the activity level of the corresponding kinase.

Kinase-substrate pairs refine treatment options
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Figure 4.5. Druggability analysis of single and paired events in 77 breast cancer
samples. (a) Heatmap of regulated kinase-substrate pairs where the kinase or the substrate is
a potential druggable target. The sample-pair showing outlier pair event is outlined. Only the
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top 3 regulated pairs were shown for each kinase when there were more than 3 pairs showi
To inform targeted

kinase-substrate outliers. (b) Druggable events identified in the mutation, CNV, RNA,

treatment,

protein, and phospho-pair level for breast cancer samples in the same subtype order.

druggability analysis has traditionally focused on detecting single activating events, such as
EGFR mutation, PIK3CA mutation, and ERBB2 amplification13,92. While these events alone can
predict treatment response, co-occurrence of elevated kinase-substrate phosphorylation can
confirm aberrant activation and reveal new treatment options. We conducted druggability
analysis for the significant cis and trans kinase-substrate pairs by screening 68 druggable genes
with potential inhibitors 120 that are abundantly expressed in our breast cancer samples
(Methods). We used abundance levels of both the kinase and substrate phosphosite to construct a
kinase-substrate pair score and identified samples showing 2 standard deviations above cohort
medians in their scores (Methods).

Among the 286 associated kinase-substrate pairs, we identified 164 outlier events among 113
unique pairs (Figure 4.5a). Outliers of the cis pair ERBB2:ERBB2 p.S1151 were found in 5
HER2-positive samples. The cis BRAF:BRAF p.S364 pair and the trans MAPK14:FOXO3
p.S413 pairs were found exclusively in 4 and 3 luminal B breast cancers, respectively. SRC and
SYC-regulated trans pairs also showed higher levels in luminal B breast cancers. Pairs
associated with MAP kinases, such as MAPK3:PALLD p.S55, MAPK3:IL16 p.S584 and
MAPK8:JUN p.T62, showed higher levels and several pair outliers in luminal A breast cancers.
In samples without prominent ERBB2 signaling, we observed other alternative outlier pairs
triggered by other receptor tyrosine kinases, including EGFR regulated trans pairs and IGF1Rregulated cis pair IGF1R: IGF1R p.S1365. In the 24 breast cancer PDXs, we also discovered
115

outliers of many regulated pairs including ERBB2:ERBB2 p.S1151, BRAF:BRAF p.S364 and
EGFR:PLCG1 p.S1222, supporting their prevalence in breast cancer.

We compared the candidate targets identified through paired druggability analysis and
conventional single driver analysis (Figure 4.5b), where we compiled mutations, CNV, RNA,
protein levels of the same 68 expressed, potentially druggable genes (Methods). We observed
concordant single driver events with outlier pair events for kinases including AKT1, BRAF,
ERBB2, IGF1R and RAF1. Samples with ERBB2, IGF1R and RAF1 copy number amplified
outliers often show high expression of the respective kinases-substrate pairs (Figure 4.5b).
However, single driver events do not guarantee activated signaling of the kinase-substrate pairs
for these kinases and phosphoproteomics data confirms abberant regulation. For example, some
samples with PIK3CA mutation, ERBB2 mutation, or RAF1 copy number amplification did not
show activated phospho-signaling (Figure 4.5b). To further confirm the effect of these effects
and treatment option for each patient, observing concurrent activation of downstream targets
may be required.

On the other hand, active signaling events may occur in samples without mutations or expression
aberrations of the kinase. This is particularly evident in both human and PDX samples with
outlier MAPK3 and MAPK14 trans pairs (Figure 4.5b). Only 2 out of 7 samples with outlier
MAPK3 trans pairs showed MAP3K1 mutations and all 5 samples with outlier MAPK14 trans
pairs did not carry MAP3K1 or MAP2K4 mutations, suggesting MAP kinases may be activated
by other upstream signaling mechanisms rather than directly being altered at the sequence or
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expression levels. We also observed some of these outlier pair events in absence of single driver
events for AKT1, BRAF and EGFR (Figure 4.5b) that require further investigation.

Activated kinase-substrate cascades

We further extended the analysis from pairs to two-level signaling cascades that include the first
and second degree substrates of the druggable kinase (Methods). We hypothesize in these
signaling cascades, the activated kinases could trigger phosphorylation of various targets through
multiple steps and represent good opportunities for targeted inhibition treatment.

Out of 28 kinases associated with at least one cis or trans-regulated phosphosite, 16 also had
second-degree substrates. AKT1, BRAF, EGFR, JAK2, PRKCE and PLK1 showed cis and trans
interactions that may help confirm activity levels (Figure 4.6). In addition to its cis associations,
AKT1 also associated with phosphosites of ILF3, ETS1 and GSK3A, and GSK3A is in turn
associated with 3 phosphosites of NDRG1, 2 sites of RICTOR and 1 site each in LARP1 and
ANKS1A (Figure 4.6a). BRAF also has multiple cis-regulated phosphosites and is associated
with phospho-MAP2K1/2 (MEK1/2), which are associated with downstream phosphosites at
MTA1, KRT8 and PRKCD (Figure 4.6b). Finally, high levels of EGFR phosphorylation were
mostly observed in basal subtype breast cancers, and these tumors also exhibited high
phosphosite levels in GAB1, PLCG1, FAM129B and PTK2; PTK2 phosphoprotein is further
associated with phosphosites of PPP1R13L and PXN (Figure 4.6c). The association of the
primary druggable kinase with its signaling cascade could strengthen the rationale for targeted
inhibition in tumors showing co-activation.
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Figure 4.6. Druggable kinase-substrate cascades originating from (a) AKT1 (b) BRAF and
(c) EGFR in the 77 breast cancer samples. The samples in the heatmap were ordered by the
phosphoprotein level of each of the kinases. For each node in each network diagram, the
color represents the relative level of basal compared to luminal A/B breast cancers, where
blue indicates higher level in luminal and red indicates higher level in basal tumors. For the
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edges, the darkness of the color is scaled by the correlation coefficient and the width is sca
Kinase-substrate

by -log(FDR) of the association.

pairs correlated with clinical and immune features
Lastly, we sought to identify kinase-substrate pairs associated with clinical characteristics of
breast cancer. We conducted regression analysis between the correlation score for each kinasesubstrate pair and pathogical stage and survival adjusted for their PAM50 subtypes (Methods).
175 pairs showed potential association (P < 0.05) with pathogical stage (Figure 4.7a); pairs
stemmed from MAP kinases, including MAPK11:PPP1R13L p.S113, MAPK9:STAT3 p.S727
and MAPK8:NFATC1 p.S359, showed top correlations with earlier clinical stage. 83 pairs are
potentially associated with survival using the Cox proportional hazards model (Figure 4.7b).
Notably, these pairs are dominated by 32 CDK1 and 29 CDK2 trans-regulated pairs correlated
with protective effects (Hazard Rate Ratio < 1) in breast cancer survival.

We identified 160 pairs potentially associated (P < 0.05, 40 pairs with FDR < 0.05) with
transcriptomically-derived immune score as calculated by the ESTIMATE algorithm131
(Methods, Figure 4.7c,d). We then specifically asked whether the associated pairs showed direct
overlap with the immune-related genes. Our analysis showed that 15 pairs positively associated
with the immune scores have their respective substrates as immune genes; the significant
enrichment of immune genes in identified pairs (15/160 vs. 11/918, Fisher’s Exact Test, P =
3.58e-07) validated our approach. The remaining 145 pairs (the top 6 pairs shown in Figure 4.7d)
represent signaling networks simultaneously activated with up-regulation of the immune genes
and functions.
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Figure 4.7. Clinical association of kinase-substrate pairs. (a) Volcano plot showing
association of kinase-substrate pairs with pathological stage. Positive coefficient denotes
higher kinase-substrate scores associating with more advanced pathological stage. (b)
Volcano plot showing association of kinase-substrate pairs with survival. Hazard rate ratios
greater than 1 denote higher kinase-substrate scores associating with poor survival. (c)
Volcano plot showing association of kinase-substrate pairs with transcriptome-based immune
signature score, as calculated by the ESTIMATE algorithm. Positive coefficients denote
higher kinase-substrate scores associating with higher immune scores. The color of each pair
indicates whether its kinase or substrate belongs to the immune gene list used by
ESTIMATE. (d) Top kinase-substrate pairs (P < 1e-6) associated with immune scores where
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each dot indicates one breast cancer sample.

4.3 Discussion

Herein, we present a quantitative characterization of kinase-substrate pairs in breast cancer
(Figure 4.1d). The high-throughput dataset generated by LC-MS/MS enabled global assessment
of 33,239 phosphosites, 19,521 of which were not observed in two of the most comprehensive
phosphosite databases, UniProt and Phospho.ELM (Figure 4.1a,b). Our analysis allowed us to
identify 2,134 (387 cis and 1,747 trans) kinase/substrate regulatory relationships; using the same
pipeline, analysis based on RPPA-detected phosphosites only found 4 and seldom interrogated
more than one phosphosite on a protein, further stressing the need of evaluating interactions in
vivo through global phosphoproteomics. Strikingly, our study discovered 806 novel regulated
phosphosites (Figure 4.1e) from a wide spectrum of genes and gene families, regulated by
various protein kinases. This result clearly suggests that more regulated, likely cancer-specific
phosphosites will emerge in additional, even larger mass spectrometry based cancer proteome
studies. While our analyses advances towards a more comprehensive cataloging of phosphoregulations, expanding the current sample size would be required to fully establish and discover
associations (Figure 4.7). The serine-rich dataset in this study may also be complemented by
other techniques enriching for tyrosine residues132-134.

We identified 61.4% (387/630) phosphosites of kinases showing significant cis-regulation, many
of which were concentrated in known or nominated breast cancer genes such as ERBB2,
RRPS6KA4, NEK9, RIPK2 and PAK1 (Figure 4.2). In contrast, only 4.51% (1,747/38,710)
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trans kinase-substrate pairs showed significant co-regulation (Figure 4.3). It is possible that trans
substrate usage may be highly tissue-specific and some of the previously curated pairs do not
interact in breast cancer. Another possibility is that some kinase-substrate pairs established
through in vitro evidence are not relevant in physiological environments, although the validation
rate for in vivo and in vitro pairs do not differ significantly. Future investigation using data
across tissue and cancer types would be pivotal in addressing whether we observe tissue-specific
usage of kinase-substrate pairs. Such studies could also reveal the consistently high/low pairs
(Figure 4.1d) in each cancer type and highlight cancer-specific signaling.

Our direct, quantitative observation of kinase-substrate pairs complement previous studies
focusing on singleton drivers. Conventionally, pathways were mostly constructed by linking
single candidate driver genes (such as significantly mutated genes or focally amplified genes)
through known interactions. Our approach detects the co-regulation of the gene pairs in vivo, and
thus directly validates the signaling impact of driver events in each sample. This approach also
enabled us to build relevant sub-cascades stemming from potentially druggable kinases AKT1,
BRAF and EGFR (Figure 4.6). To compare with other network-generating studies, we also
constructed a network of all observed regulations. However, such approaches may obfuscate
activated subnetworks as downstream phosphorylation targets could be mediated by multiple
kinases.

This first large-scale examination of over 33,000 phosphosites in breast cancers sets a foundation
for druggable analysis of kinase-substrate pairs beyond singleton druggable events (Figure 4.5).
Predictive value of response to targeted treament has been limited in samples for some clearly122

definied driver events in cancer (ex. PIK3CA mutation status failing to predict treatment
response to PI3K inhibitor). Co-occurrence of downstream activating events, as we have
observed for AKT1, BRAF, ERBB2, IGF1R and RAF1 (Figure 4.5b), may further support
targeted inhibition. In both breast cancer PDXs showing ERBB2:ERBB2 p.S1151 cis outlier
pairs, lapatinib treatment significantly reduced tumor growth120. Resistance mechanisms often
consists of rewiring of signaling pathways and could be further explored through highthroughput proteomics and approaches developed in this study. Further, we identified outlier
kinase-substrate pairs in samples without singleton events for kinases including EGFR, MAPK3
and MAPK14 (Figure 4.5b). Inhibition of the MAP2K1/2 (MEK1/2) upstream of MAP kinases
surpressed the MAPK signaling pathway and its combinatory treatment with RTK inhibitors
have resulted in tumor regression of triple-negative breast tumors29. Our discovery of MAPK
mediated pairs reveals therapeutic opportunities.

In conclusion, signaling networks are crucially important in cancer. However, large-scale omic
studies to date have mainly focused on singling out individual driver events and rarely
investigate their signaling impact. Studying kinase-substrate relations in vivo, and most
particularly in tumor samples from patients undergoing therapy will uncover the wiring of
signaling networks in each tumor and likely improve treatment approaches.

123

4.4 Methods

Sample Description
Samples of human breast cancer were as described in the CPTAC marker paper23,27. These
comprise of 77 breast cancer samples that showing unimodal distribution in proteomes, their 3
technical replicates and 3 normal breast samples. Samples of the 24 PDX breast cancer were as
described previously120.

Data Generation
TCGA genomics data
The TCGA somatic mutation data, level-3 segment-based copy number data, level-3 normalized
RNA expression data, were downloaded from firehose (archive date 2014-10-17). We then
converted the segment-based copy number data to the gene-based copy number data by using the
RefSeq database (version 20130727). The CNV ploidity number is divided by 2 and then log2transformed to obtain the final CNV levels for analysis. We also log2-transformed the RSEM
values of RNA expression data.
TCGA RPPA data
Normalized RPPA data of TCGA tumors were downloaded from The Cancer Protein Atlas
(TCPA , archive date 2015-10-30). The RPPA data were normalized across batches using
replicates-based normalization (RBN) as previously described135.

Global Proteomics data
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Global proteomics data for the human samples were downloaded from the Mertins et al. breast
cancer study83. Global proteomics data for the PDX samples were downloaded from the Huang
et al. breast cancer PDX study120. As previously described, 2-component Gaussian mixture
model-based normalization algorithm was used to normalize the data and accomandate both
consistently and differentially-expressed proteins and phosphosites within each sample. Further,
proteins and phosphosites were required to have observed (non-missing) iTRAQ ratios in at least
30 samples and an overall standard deviation larger than 0.5 (across all samples where they were
observed).

Protein and phosphorylation databases
UniProt: We applied HotSpot3D (v1.1.1) which accesses crystal structures from RCSB Protein
Data Bank (PDB) and calculates residue distances using the average distance-measure option in
preprocessing (structures processed January 2017)74. We used a custom Perl script to retrieve
phosphosites, active sites, and binding sites (ie. features matching MOD_RES, ACT_SITE,
BINDING, or SITE) from UniProt (date accessed 1/30/2017)136.
PhosphositePlus: We downloaded the PhosphositePlus124,137 database (2/11/2016). We then
extracted the kinase-substrate pairs where both are proteins are from human from the kinasesubstrate database for downstream analysis.
To identify phosphosites known in cancer, we filtered the disease-associated sites database for
cancer terms (ex. cancer, *oma and leukemia). The sites that were not matched to a valid
genomic coordinate by transvar were excluded, and the remainder sites were further reviewed to
retain 261 sites, where 84 unique sites were quantified in our dataset.
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Phospho.ELM: We downloaded the phospho.ELM database from PhosphositePlus (2/11/2016).
We then extracted the phosphosites mapping to human proteins, and reverse-translated to their
unique genomic positions using transvar.
PhosphoNetwork: We downloaded the Supplementary Tables from Newman et al.31 and derived
the predicted kinase-substrate pairs from the file comKSI.csv. We then further filtered out the
pairs already observed in PhosphositePlus and combine the remaining pairs with pairs from
PhosphositePlus for analysis.

Bioinformatics analyses
Cross data type and database integration
All gene names were converted to HUGO Gene Nomenclature Committee’s approved gene
names for comparison across levels and datasets. To match the exact phosphosite (ex.
PIK3CA:NP_006209.2:s312) across databases, all phosphosites are reversely-mapped to their
genomic position (ex. chr3:g.178921452_178921454) using transvar 71.

Regulated kinase-substrate pairs regression analysis
We obtained 3,245 unique kinase-substrate pairs in the PhosphositePlus database and an
additional 1,752 kinase-substrate pairs from the PhosphoNetwork database. We then applied the
linear regression model as implemented in glm function in R to test for the relation between
kinase and substrate phosphosite. The tests are independently conducted for cis and trans
interactions in the cohort of 77 human breast cancer samples. For cis-interactions, we used
kinase protein expression as the independent variable and each of the kinase’s phosphosite level
as the dependent variable. For trans-interactions, we used kinase phospho-protein expression and
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the substrate’s protein expression as independent variables and the substrate’s phosphosite level
as the dependent variables. For each kinase-substrate-phosphosite pair to be tested, we required
both kinase protein/phosphoprotein expression and phosphosite phosphorylation to be observed
in at least 10 samples in the respective datasets and the overlapped dataset. The resulting p
values were adjusted using the Benjamini-Hochberg procedure to FDR.

We determined kinase-phosphosite pairs as validated if they showed P value under 0.05 and
positive regression coefficients in the PDX cohort. For the kinase-phosphosite pairs showing top
significant associations in the regression analysis, we calculated the average of phosphorylation
level for each of the substrate phosphosite and protein expression of the kinase within each of 4
breast cancer subtypes (Basal, Her2, LumA and LumB) for display in Figure 4.2 and 3.3.

Kinase group and family enrichment analysis
To test for whether kinases showing significant cis or trans correlations are enriched in kinase
groups and families, we applied one tailed Fisher’s exact test under a null hypothesis that the
odds ratio of associated kinases in the family are not greater. The universe of kinases for each of
the cis and trans test was defined as the total tested kinase, and the 2-by-2 table is constructed by
(1) whether the kinase belongs to the kinase group/family, and (2) whether the kinase has any
significant correlations.

Structural and co-phosphorylation analysis
We used HotSpot3D74 to generate pairwise linear and 3D distance between residues within 1,288
proteins with available PDB structure. The active sites are mapped based on data from the RSCB
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PDB as of January 2017 (http://www.rcsb.org/pdb/home/home.do). Pearson’s correlation
coefficients and adjusted P values are then calculated for each pair of two phosphosites within
these proteins. We limited this correlation analysis to pairs of phosphosites jointly observed in at
least 5 samples in the breast cancer cohort. For linear examinations of association landscapes, the
lolliplots were generated and modified using the PCGP protein painter
(http://explore.pediatriccancergenomeproject.org/proteinPainter).

Druggable kinase-substrate pairs and cascades analysis
We compiled a list 76 druggable genes along with their respective drugs, from established public
databases as previously described120. We then limit the analysis to the 68 genes with per-sample
average RSEM value greater than 100. We searched for significantly associated kinase-substrate
pairs where either the kinase or substrate belongs to the set of druggable genes. The score of each
pair is calculated as the sum of standardized kinase and substrate phosphosite levels:
!"#$%&'(&)*&+,%+' =

!"#$%&' − /"#$%&' !&)*&+,%+' − /&)*&+,%+'
+
0"#$%&'
0&)*&+,%+'

whereby / is the mean and 0 is the standard deviation.

To identify druggable outliers in the conventional method, we scanned for events at the somatic
mutation, CNV, RNA and protein expression for each gene. CNV, RNA, and protein expression
outliers are identified as the ones greater than 2 interquartile ranges (IQR) above median as
previously described 83. We then complemented this conventional single-event analysis by
identifying outliers using the kinase-substrate score.
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To define the druggable cascade of each of the druggable kinase, we extracted all significantly
associated cis phosphosites and its first-degree correlated trans substrate phosphosites. We then
expanded one level beyond and extracted additional trans phosphosites associated with the
phosphoprotein level of the first-degree substrates. The resulting cascades were visualized using
heatmap showing levels of each protein/phosphoprotein/phosphosite and a network diagram
using Cytoscape 138.

Clinical and immune correlation analysis
We conducted association analysis between the score for each kinase-substrate pair and
pathogical stage, survival, radiation therapy, and immune signatures adjusted for their PAM50
subtypes. For continuous variables, including pathogical stage and immune scores, we used a
Gaussian linear regression. For whether the sample has gone through radition therapy, we used a
logistic regression model. We used the Cox proportional Hazards model for survival analysis.
The resulting p values were adjusted to FDR using the Benjamini-Hochberg procedure.
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Conclusion

Revealing fundamental interactions between DNA, RNA and protein empowered
research and application of molecular biology in the past century. Similarly, omics data at each
level urgently require integration. I plan build a research program to further develop
bioinformatics tools and integrate large-scale omics. Inference between genomics variants,
transcriptome, proteome, PTMs and signaling networks will facilitate our understanding of each
oncogenic event. Finally, their integration will help us understand the molecular dynamics of
cancer at a comprehensive scale and inform personalized medicine.
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